Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptide Changes: FDA Status, Safety and Dosing Updates

This page logs material changes to the 150 peptide pages on this site. That covers FDA and compounding status, safety notes, dosing data, evidence grades and corrections. Every entry carries its event date and a primary source.

195 entries150 peptides coveredRecord began Subscribe to the feed

Upcoming

Scheduled reviews, deadlines and estimated trial dates, from the same kind of primary sources. A date here is not an outcome. Any of them can go in your calendar.

One calendar with every upcoming date on this page. It updates when a date moves and holds nothing about you.

  1. Committee review

    FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.

    What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.

    Peptides: LL-37, GHK-Cu, Dihexa, Melanotan II, PEG-MGF

  2. Company-stated plan

    Eli Lilly plans to submit a Biologics License Application for retatrutide to FDA in the first quarter of 2027, per Lilly.

    What this does not mean: A planned filing is not an approval. Company timelines can slip, and FDA review starts only after a filing is accepted.

    Peptides: Retatrutide

  3. Trial primary completion, estimated

    REDEFINE 3, the Phase 3 heart outcomes trial of CagriSema, has an estimated primary completion date, per ClinicalTrials.gov.

    What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.

    Peptides: CagriSema

  4. Trial primary completion, estimated

    TRIUMPH-6, a Phase 3 trial of retatrutide for keeping lost weight off, has an estimated primary completion month, per ClinicalTrials.gov.

    What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.

    Peptides: Retatrutide

  5. Trial primary completion, estimated

    A Phase 2 trial of tesamorelin with exercise for physical function in HIV has an estimated primary completion date, per ClinicalTrials.gov.

    What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.

    Peptides: Tesamorelin

  6. Trial primary completion, estimated

    LIVERAGE, a Phase 3 trial of survodutide in MASH with moderate or advanced fibrosis, has an estimated primary completion date, per ClinicalTrials.gov.

    What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.

    Peptides: Survodutide

Latest Changes

October 2026

  1. Safety

    Corrected Oct 29, 2026: tipranavir trough levels ran about 45% higher with enfuvirtide in Phase 3 trials; no dose change is advised, per the APTIVUS label.

    Before: Tipranavir/ritonavir may slightly reduce enfuvirtide concentrations; no dose adjustment After: Tipranavir trough levels about 45% higher with enfuvirtide in the Phase 3 trials; cause unknown; no dose change (APTIVUS label, section 7)

    What this does not mean: No new study, and the label recommends no dose change. The page had said tipranavir/ritonavir may slightly lower enfuvirtide levels. The label reports tipranavir going up instead, and its cause is not known.

    Peptides: Enfuvirtide (Fuzeon)

    Source: APTIVUS (tipranavir) prescribing information (openFDA label record, SPL version 19, effective Jun 18, 2025), section 7, Table 4, the enfuvirtide row (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  2. Evidence

    Corrected Oct 20, 2026: VIP's research stage is phase 3, not 1; IV aviptadil (synthetic VIP) had a published phase 3 (TESICO), per PubMed (PMID 37348524).

    Before: Phase 1 After: Phase 3 (TESICO, IV aviptadil in COVID-19 respiratory failure, PMID 37348524)

    What this does not mean: No new study was published, and the dose tiers are unchanged. TESICO gave IV aviptadil for COVID-19 respiratory failure and stopped it for futility. The intranasal CIRS use on this page rests on one 20-patient open-label study.

    Peptides: VIP (Vasoactive Intestinal Peptide)

    Source: Lancet Respir Med 2023, Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (Brown et al.; registered as phase 3, NCT04843761) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  3. Dosing

    Corrected Oct 20, 2026: vasopressin's aggressive tier is 0.07 units/min, the top of the septic-shock range, per the Vasostrict label, section 2.2.

    Before: Aggressive tier 0.04 IU, Continuous IV infusion (units/minute), no caveat After: Aggressive tier 0.07 IU, Continuous IV infusion (units/minute), with a caveat: top of the label septic-shock range, limited data above it

    What this does not mean: Not a target rate. The label never states the old 0.04. It starts septic shock at 0.01 and post-cardiotomy shock at 0.03 units/min, has limited data above 0.07 and 0.1, and expects more adverse reactions at higher doses.

    Peptides: Vasopressin (Vasostrict)

    Source: Vasostrict (vasopressin injection) prescribing information, section 2.2 (openFDA label record, SPL version 49, effective Apr 21, 2026) (opens in a new tab) · Saved copy

  4. Safety

    Corrected Oct 20, 2026: vasopressin's septic-shock ceiling is 0.07 units/min, with limited data above it, per the Vasostrict label, section 2.2.

    Before: Infusion rates above 0.04 U/min carry significantly raised risk. After: Rates above 0.04 U/min may lead to adverse events (PMID 11555538); guidelines hold 0.03 U/min; the label's septic-shock ceiling is 0.07 U/min, with limited data above it (section 2.2)

    What this does not mean: The old line said rates above 0.04 carry significantly raised risk, with no source. It now cites Holmes 2001 (PMID 11555538): above 0.04 may lead to adverse events, likely from vasoconstriction.

    Peptides: Vasopressin (Vasostrict)

    Source: Vasostrict (vasopressin injection) prescribing information, section 2.2 (openFDA label record, SPL version 49, effective Apr 21, 2026) (opens in a new tab) · Saved copy

  5. Safety

    Corrected Oct 20, 2026: pregnancy is a label caution for PT-141, not a contraindication, per the Vyleesi label, sections 4, 8.1 and 8.3.

    Before: Pregnancy is a contraindication. After: Pregnancy is not a label contraindication (section 4), but the label does not recommend use in pregnancy (sections 8.1 and 8.3).

    What this does not mean: The caution stands. Animal studies point to possible fetal harm, so the label advises effective contraception and stopping if pregnancy is suspected. Section 4 lists only uncontrolled hypertension and known cardiovascular disease.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, sections 4, 8.1, 8.2 and 8.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  6. Safety

    Corrected Oct 20, 2026: pregnancy and breastfeeding are not PT-141 label contraindications, per the Vyleesi label, sections 4 and 8.1 to 8.3.

    Before: Pregnancy or breastfeeding After: Pregnancy or breastfeeding: not label contraindications, but the label does not recommend use in pregnancy, says to stop if pregnancy is suspected (sections 8.1 and 8.3) and has no human milk data (section 8.2)

    What this does not mean: Pregnancy stays on the list as a caution: the label does not recommend use in pregnancy and says to stop if pregnancy is suspected. It has no data on bremelanotide in human milk.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, sections 4, 8.1, 8.2 and 8.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  7. Safety

    Corrected Oct 20, 2026: hypersensitivity is not a PT-141 label contraindication, per the Vyleesi label, section 4.

    Before: Known hypersensitivity to bremelanotide or excipients is a contraindication. After: The label does not list hypersensitivity as a contraindication; stop if an allergic reaction occurs.

    What this does not mean: The allergy caution stays: stop PT-141 if an allergic reaction occurs. Section 4 names only uncontrolled hypertension and known cardiovascular disease.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, section 4 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  8. Safety

    Corrected Oct 20, 2026: known hypersensitivity stays listed for PT-141 as a caution, not a label contraindication, per the Vyleesi label, section 4.

    Before: Known hypersensitivity to bremelanotide or any excipients After: Known hypersensitivity to bremelanotide or any excipient: not a label contraindication (section 4 names only uncontrolled hypertension and known cardiovascular disease)

    What this does not mean: An allergy to bremelanotide or an excipient is still a reason not to use it. The label simply does not name it; section 4 lists uncontrolled hypertension and known cardiovascular disease.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, section 4 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  9. Safety

    Corrected Oct 20, 2026: PT-141 needs no dose adjustment in mild to moderate hepatic impairment, per the Vyleesi label, sections 8.7 and 12.3.

    Before: Moderate to severe hepatic impairment increases drug exposure and should prompt dose adjustment or avoidance. After: Exposure rises 1.2-fold (mild) and 1.7-fold (moderate), yet the label recommends no dose adjustment for mild to moderate impairment; severe was not studied, use with caution (section 8.7).

    What this does not mean: Exposure still rises 1.2-fold in mild and 1.7-fold in moderate impairment. Severe (Child-Pugh C) impairment was not studied, and the label says use with caution there.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, sections 8.7 and 12.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  10. Safety

    Corrected Oct 20, 2026: only severe hepatic impairment carries a PT-141 caution; mild to moderate needs no dose change, per the Vyleesi label, section 8.7.

    Before: Hepatic impairment (moderate to severe): increased drug exposure After: Severe hepatic impairment (Child-Pugh C): not studied, use with caution (section 8.7); no dose adjustment for mild to moderate (Child-Pugh A and B)

    What this does not mean: Severe (Child-Pugh C) impairment was not studied, so the label says use with caution. The page had listed moderate to severe impairment as a contraindication.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, sections 8.7 and 12.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  11. Safety

    Corrected Oct 20, 2026: GHK-Cu side effects drop an unsourced line that injected copper stays below toxic levels; the copper limit is for intake, per IOM 2001.

    Before: At typical community doses (1 to 2 mg/day subcutaneous), the copper load stays well below toxic thresholds. After: Line dropped: no upper limit is set for injected copper (the IOM limit covers intake from food, water and supplements); the accumulation caution and copper checks stay.

    What this does not mean: No new copper risk was found, and the dose tiers are unchanged. The IOM set its 10 mg a day upper limit for copper from food, water and supplements. It gives no figure for injected copper.

    Peptides: GHK-Cu

    Source: Institute of Medicine 2001, Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, chapter 7 (Copper): adult upper limit 10,000 mcg/day, set on liver damage (PMID 25057538) (opens in a new tab) · Archived snapshot (opens in a new tab)

  12. Dosing

    Corrected Oct 20, 2026: cortexin's aggressive tier is 20 mg once daily, the arm Fedin 2018 gave, not 10 mg twice daily, per the full text (PMID 30335070).

    Before: Aggressive 10 mg twice daily, noted: the trial gave 20 mg as one IM injection once daily After: Aggressive 20 mg once daily, the Fedin 2018 trial arm (PMID 30335070), noted: 20 mg is two 10 mg vials

    What this does not mean: The daily total is unchanged. The trial gave 20 mg IM once daily for 10 days to 69 adults aged 50 to 80 with chronic cerebral ischemia. No trial tested healthy adults or a twice-daily split.

    Peptides: Cortexin

    Source: Zh Nevrol Psikhiatr Im S S Korsakova 2018, Dose-dependent effects of cortexin in chronic cerebral ischemia (Fedin et al., PMID 30335070), full text on the publisher page: 69 patients got 20 mg IM once daily (opens in a new tab) · Archived snapshot (opens in a new tab)

  13. Evidence

    Corrected Oct 20, 2026: AICAR's research stage is phase 3, not 2; IV acadesine had a published phase 3 (RED-CABG), per PubMed (PMID 22782417).

    Before: Phase 2 After: Phase 3 (RED-CABG, IV acadesine in bypass surgery, PMID 22782417)

    What this does not mean: No new study was published, and the dose tiers are unchanged. RED-CABG gave acadesine (AICAR) IV during bypass surgery and stopped for futility after 3,080 of a planned 7,500 patients. It did not test subcutaneous use.

    Peptides: AICAR (Acadesine)

    Source: JAMA 2012, Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial (Newman et al.; registered as phase 3, NCT00872001) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  14. Safety

    Corrected Oct 19, 2026: PT-141 with oral naltrexone is a combination to avoid, not a listed contraindication, per the Vyleesi label, section 7.2.

    Before: a pharmacokinetic interaction serious enough that the FDA lists it as a contraindication. After: a pharmacokinetic interaction serious enough that the FDA label says to avoid the combination (section 7.2).

    What this does not mean: The interaction is unchanged: PT-141 may significantly lower oral naltrexone exposure, so people treated for alcohol or opioid addiction should avoid it. Only the label section the page named was wrong.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, sections 4 and 7.2 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  15. Safety

    Corrected Oct 19, 2026: oral naltrexone is a drug interaction to avoid with PT-141, not a contraindication, per the Vyleesi label, sections 4 and 7.2.

    Before: Listed as a contraindication in FDA prescribing information. After: The label says to avoid oral naltrexone products for alcohol or opioid addiction (section 7.2).

    What this does not mean: The advice stands: avoid PT-141 with oral naltrexone products for alcohol or opioid addiction, since it may cut naltrexone exposure. The label's contraindications are uncontrolled hypertension and known cardiovascular disease.

    Peptides: PT-141

    Source: Vyleesi (bremelanotide injection) prescribing information, sections 4 and 7.2 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  16. Dosing

    Corrected Oct 19, 2026: GHK-Cu's moderate tier is 2 mg daily, not 2.5 mg, the top of its 1 to 2 mg community range; no trial set an injected dose, per PubMed.

    Before: Beginner 1,000, moderate 2,500, aggressive 3,000 mcg daily After: Beginner 1,000, moderate 2,000, aggressive 3,000 mcg daily

    What this does not mean: No new study, and no dose is newly supported: the tiers are community figures. GHK-Cu's human trials are topical, such as Miller 2006; no human study has tested it alone as an injection. Beginner 1 mg and aggressive 3 mg are unchanged.

    Peptides: GHK-Cu

    Source: Arch Facial Plast Surg 2006, Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (Miller et al.), a randomized trial of topical GHK-Cu (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  17. Dosing

    Corrected Oct 18, 2026: vasopressin's tiers are infusion rates in units per minute, not daily doses, per the Vasostrict label, section 2.2.

    Before: 0.01, 0.03 and 0.04 IU, each labelled Daily After: 0.01, 0.03 and 0.04 IU, each labelled Continuous IV infusion (units/minute)

    What this does not mean: The numbers did not change. The label starts septic shock at 0.01 and post-cardiotomy shock at 0.03 units per minute, titrated by a clinician on a pump.

    Peptides: Vasopressin (Vasostrict)

    Source: Vasostrict (vasopressin injection) prescribing information, section 2.2 (openFDA label record, SPL version 49, effective Apr 21, 2026) (opens in a new tab) · Saved copy

  18. Evidence

    Corrected Oct 18, 2026: thymosin beta-4's research stage is phase 3, not 1; RGN-259 eye drops had a published phase 3 (SEER-1), per PubMed (PMID 36613994).

    Before: Phase 1 After: Phase 3 (SEER-1, RGN-259 eye drops, PMID 36613994)

    What this does not mean: No new study was published, and the dose tiers are unchanged. The phase 3 trials tested RGN-259 eye drops; SEER-1 stopped at 18 patients, short of significance (p=0.0656). ClinicalTrials.gov lists no phase 3 of injected thymosin beta-4.

    Peptides: Thymosin Beta-4

    Source: Int J Mol Sci 2023, 0.1% RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy: randomized, placebo-controlled, double-masked phase III trial (SEER-1; Sosne et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  19. Safety

    Corrected Oct 18, 2026: setmelanotide's kidney note now gives the label's lower dose for severe impairment in place of no adjustment, per the Imcivree label.

    Before: Renal impairment raises exposure 13-96%: no dose adjustment per label, but monitor After: Severe impairment lowers the label dose (0.5 mg start; 1.5 mg, 1 mg or 0.5 mg maintenance by age and weight); not recommended under 20 kg at ages 2 to under 6, in acquired hypothalamic obesity or in end-stage renal disease

    Peptides: Setmelanotide

    Source: Imcivree (setmelanotide) prescribing information, sections 2.4 (with Table 4) and 8.6 (openFDA label record, SPL version 14, effective Apr 1, 2026; captured as the same-version DailyMed SPL XML, Table 4 image beside it) (opens in a new tab) · Saved copy

  20. Safety

    Corrected Oct 18, 2026: severe kidney impairment cuts setmelanotide to a 0.5 mg start, then 0.5 to 1.5 mg by age and weight, per the Imcivree label.

    Before: Renal impairment raises exposure 13 to 96%; no dose adjustment is required per label After: Severe impairment (eGFR 15 to 29): 0.5 mg start; maintenance 1.5 mg from age 12, 1 mg at ages 6 to under 12, and at ages 2 to under 6 0.5 mg (20 to under 30 kg) or 1 mg (30 kg and up); not recommended under 20 kg, in acquired hypothalamic obesity or below eGFR 15

    What this does not mean: Mild or moderate kidney impairment still needs no dose change, and the usual doses did not change. Severe impairment was always in the label; the page said no adjustment was needed.

    Peptides: Setmelanotide

    Source: Imcivree (setmelanotide) prescribing information, sections 2.4 (with Table 4) and 8.6 (openFDA label record, SPL version 14, effective Apr 1, 2026; captured as the same-version DailyMed SPL XML, Table 4 image beside it) (opens in a new tab) · Saved copy

  21. Safety

    Corrected Oct 18, 2026: pasireotide's glucose plan follows Witek 2024, metformin then a GLP-1 agonist or SGLT-2 inhibitor, no DPP-4, per PubMed (PMID 39735646).

    Before: Metformin 500 mg twice daily above 126 mg/dL, then DPP-4 inhibitors or GLP-1 receptor agonists After: Metformin first from prediabetes, then a GLP-1 receptor agonist or an SGLT-2 inhibitor, insulin last; DPP-4 inhibitors left out of the algorithm

    What this does not mean: High blood sugar is still the main risk, in about 73% of patients. The review sets no metformin dose and starts metformin at prediabetes, not at 126 mg/dL.

    Peptides: Pasireotide (Signifor)

    Source: Front Endocrinol 2024, Pasireotide-induced hyperglycemia in Cushing's disease and acromegaly: a clinical perspective and algorithms proposal (Witek et al.), full text PMC11672337 (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  22. Safety

    Corrected Oct 18, 2026: nesiritide's interaction list now names IV enalaprilat, incompatible in the same IV line, per the Natrecor label, section 2.4.

    Before: Heparin, furosemide, insulin, hydralazine, bumetanide and ethacrynate sodium listed; enalaprilat missing After: IV enalaprilat: physical incompatibility per the FDA label; do not co-administer through the same IV line

    What this does not mean: No new safety finding. The page already named enalaprilat in its FAQ, guide and stacking notes; the interaction list now matches the label.

    Peptides: Nesiritide (Natrecor)

    Source: Natrecor (nesiritide) prescribing information, section 2.4 (openFDA label record, SPL version 12, effective May 15, 2020) (opens in a new tab) · Saved copy

  23. Safety

    Corrected Oct 18, 2026: a 2025 leuprolide cohort saw heart events fall from 5.4% to 2.3% but did not credit cardiology care, per PubMed (PMID 40680199).

    Before: 2,893 patients; MACE fell from 5.4% to 2.3% as cardiology co-management improved After: Retrospective cohort; 5.4% of 1,128 leuprolide patients (2018 to 2020), then 2.3% of 1,398 (Dec 2020 to Mar 2024); relugolix not linked to lower risk

    What this does not mean: Androgen deprivation still carries cardiovascular risk. A prior heart attack or stroke went with about five times the risk (HR 5.32).

    Peptides: Leuprolide (Lupron)

    Source: Urol Pract 2025, Adverse cardiovascular outcomes of individuals treated with androgen deprivation therapy (Li et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  24. Safety

    Corrected Oct 18, 2026: ghrelin's side effects no longer blame edema on raised IGF-1; IGF-1 did not differ by dose over 8 weeks, per PubMed (PMID 20186829).

    Before: Water retention and mild edema appeared in some study participants, related to sustained IGF-1 elevation from repeated GH pulses After: A review of 121 human studies: mild adverse effects in about 20% of the 939 participants with reported data, mostly flushing and stomach rumbling; in the 8-week trial, serum IGF-1 did not differ between 13 and 0.7 mcg/kg

    What this does not mean: No new safety finding. A 2013 review of 121 human studies found mild adverse effects in about 20% of the 939 participants whose 66 studies reported them, mostly flushing and stomach rumbling (PMID 23533240).

    Peptides: Ghrelin

    Source: Cancer 2010, Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study (Lundholm et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  25. Dosing

    Oct 18, 2026: cortexin's 10 mg twice-daily tier now notes that Fedin 2018 gave its 20 mg a day as one IM injection, per the full text (PMID 30335070).

    Before: Aggressive 10 mg twice daily with no note After: Aggressive 10 mg twice daily, noted: the trial gave 20 mg as one IM injection once daily; no trial tested 10 mg twice daily

    What this does not mean: The tier did not change. Its daily total matches the trial arm; only the split differs, and no trial tested it.

    Peptides: Cortexin

    Source: Zh Nevrol Psikhiatr Im S S Korsakova 2018, Dose-dependent effects of cortexin in chronic cerebral ischemia (Fedin et al., PMID 30335070), full text on the publisher page: 69 patients got 20 mg IM once daily (opens in a new tab) · Archived snapshot (opens in a new tab)

  26. Dosing

    Oct 18, 2026: CGRP's 60 mcg tier now carries its unsourced note; cited infusions ran 1.5 to 2 mcg/min for 20 minutes, per PubMed (PMID 11993614).

    Before: Aggressive 60 mcg single dose with no note After: Aggressive 60 mcg single dose, noted: unsourced; cited infusions ran 1.5 to 2 mcg/min for 20 minutes (30 to 40 mcg)

    What this does not mean: The tiers did not change. The printed chart and the page now show the same note the dosing guide already gave.

    Peptides: CGRP (Calcitonin Gene-Related Peptide)

    Source: Cephalalgia 2002, CGRP may play a causative role in migraine (Lassen et al.): 2 mcg/min IV for 20 minutes (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  27. Evidence

    Corrected Oct 18, 2026: CCK-8's half-life is about 1.3 minutes after IV dosing in healthy adults, not 2 to 5 minutes, per Kanayama 1985.

    Before: The compound's 2 to 5 minute half-life means most side effects resolve within minutes of stopping the infusion. After: The compound's half-life of about 1.3 minutes means most side effects resolve within minutes of stopping the infusion.

    What this does not mean: No new safety finding. The page's 2 to 5 minutes had no CCK-8 source; the 4.2 minutes it cited (Jebbink 1990) was measured for CCK-33. Clearance was slower in cirrhosis (2.45 min).

    Peptides: Cholecystokinin (CCK-8)

    Source: Kanayama et al., Am J Gastroenterol 1985;80(7):557-60, PMID 4014106 (CCK-8 disappearance half-time after a 2-minute IV infusion: 1.30 min healthy, 1.70 min chronic renal failure, 2.45 min cirrhosis) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  28. Safety

    Corrected Oct 18, 2026: the Miacalcin label says to consider a skin test if calcitonin allergy is suspected; it sets no test dose or cutoff, per the label.

    Before: The FDA label requires a skin test before the first dose: 0.1 mL of a 10 IU/mL dilution; a 15 mm wheal contraindicates After: With suspected hypersensitivity the label says to consider a skin test with a dilute solution, possibly via an allergist; it gives no test dose

    What this does not mean: Anaphylaxis, including deaths, is still a labeled risk, and known hypersensitivity is still a contraindication. The 10 IU/mL, 0.1 mL and 15 mm figures are not in the current label.

    Peptides: Calcitonin (Miacalcin)

    Source: Miacalcin (calcitonin salmon) injection prescribing information, section 5.1 (openFDA label record, SPL version 9, effective Apr 15, 2024) (opens in a new tab) · Saved copy

  29. Safety

    Corrected Oct 18, 2026: pregnancy is a label warning for repository corticotropin, not a contraindication; Acthar Gel may cause fetal harm, per the label.

    Before: Pregnancy is contraindicated for therapeutic corticotropin. Animal studies showed embryocidal effects. After: Pregnancy is not on either repository corticotropin label's contraindication list; Acthar Gel may cause fetal harm (section 8.1), so use it only if the benefit justifies the risk

    What this does not mean: Pregnancy still carries the warning (section 8.1). The page had said pregnancy is contraindicated for therapeutic corticotropin; neither the Acthar Gel nor the Cortrophin Gel contraindication list names it.

    Peptides: ACTH (Cosyntropin/Cortrosyn)

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  30. Safety

    Corrected Oct 18, 2026: pregnancy is a label warning for Acthar Gel, not a contraindication, per the label, sections 4 and 8.1.

    Before: Pregnancy: corticotropin has embryocidal effects in animal studies; use only if potential benefit justifies risk After: Pregnancy: not a label contraindication, but the Acthar Gel label says it may cause fetal harm (section 8.1); use only if potential benefit justifies risk

    What this does not mean: Acthar Gel may cause fetal harm, so pregnancy stays on the list as a warning. The page had cited embryocidal effects in animals; the label says its developmental effects were not adequately assessed in animals.

    Peptides: ACTH (Cosyntropin/Cortrosyn)

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  31. Correction

    Corrected Oct 17, 2026: the Oct 16 sermorelin entry called all its human data small; one cited trial treated 110 GH-deficient children, per Thorner 1996.

    What this does not mean: The evidence rating stays moderate. The adult studies are small: 19 older adults in 1997 and 10 older men for 14 days in 1992. The 1996 trial treated 110 GH-deficient children for up to a year.

    Peptides: Sermorelin

    Source: Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96. PMID 8772599 (opens in a new tab) · Archived snapshot (opens in a new tab)

  32. Safety

    Corrected Oct 17, 2026: two unnamed nesiritide IV incompatibility notes now name bumetanide and ethacrynate sodium, per the Natrecor label, section 2.4.

    Before: Two notes read "Physical incompatibility", documented in the FDA label, without naming a drug After: IV bumetanide and IV ethacrynate sodium: physical incompatibility per the FDA label; do not co-administer through the same IV line

    What this does not mean: No new safety finding. Both notes already pointed to the FDA label; they now name the drugs it lists. Heparin, insulin, hydralazine and furosemide were already named.

    Peptides: Nesiritide (Natrecor)

    Source: Natrecor (nesiritide) prescribing information, section 2.4 (openFDA label record, SPL version 12, effective May 15, 2020) (opens in a new tab) · Saved copy

  33. Dosing

    Corrected Oct 17, 2026: Kisspeptin-10's moderate and aggressive tiers are now 200 and 300 mcg; no trial tested daily injections, per FDA's 2024 briefing.

    Before: Beginner 100, moderate 300, aggressive 400 mcg daily After: Beginner 100, moderate 200, aggressive 300 mcg daily

    What this does not mean: No new study was published, and no dose is newly supported. The old 400 mcg tier sat above the page's own community ceiling of about 300 mcg a day. The tiers stay labeled speculative.

    Peptides: Kisspeptin-10

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for kisspeptin-10, October 29, 2024: no published trial assessed the safety of kisspeptin-10 given chronically or on a fixed schedule for over one day (p. 22); no study reported subcutaneous Cmax or Tmax (p. 18) (opens in a new tab) · Saved copy

  34. Safety

    Corrected Oct 17, 2026: Kisspeptin-10's side effects no longer say cycling keeps it working; no weeks-long cycle had been tested, per FDA's 2024 briefing.

    Before: Desensitization "can render the peptide pharmacologically useless if cycling protocols are not followed" After: Under continuous exposure the peptide can stop raising LH; no trial has tested whether a weeks-long on/off cycle prevents it

    What this does not mean: Desensitization is still documented with twice-daily kisspeptin-54 and continuous kisspeptin-10 infusion. Only the claim that an on/off cycle prevents it was removed.

    Peptides: Kisspeptin-10

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for kisspeptin-10, October 29, 2024: no published trial assessed the safety of kisspeptin-10 given chronically or on a fixed schedule for over one day (p. 22); no study reported subcutaneous Cmax or Tmax (p. 18) (opens in a new tab) · Saved copy

  35. Safety

    Corrected Oct 17, 2026: the hexarelin cortisol study gives no ages in its abstract, so these pages say adults, not older adults, per Rahim 1999.

    Before: In healthy older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859) After: In adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)

    What this does not mean: The finding stands: 16 weeks of twice-daily hexarelin lowered the cortisol response and left the prolactin response unchanged. Only the description of the study group changed.

    Peptides: GHRP-2, GHRP-6, Hexarelin

    Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  36. Safety

    Corrected Oct 17, 2026: GHK-Cu's safety grade is now B, not A; FDA says human data on injectable GHK-Cu are limited, per its Category 2 page.

    Before: A After: B

    What this does not mean: No new safety finding, and the doses did not change. Grade A needs extensive human data or long-established use. The human data for GHK-Cu are small topical skin studies; no human study has tested it as an injection.

    Peptides: GHK-Cu

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

  37. Safety

    Corrected Oct 17, 2026: placebo nausea in the obesity trial was 15 and 11 percent, and the 73 percent peak came at 140 mg twice daily, per NCT04707313.

    Before: Nausea 73 percent in the highest-dose obesity arms versus 12.5 percent on placebo After: Nausea 73 percent in one obesity arm (140 mg twice daily) versus 15 and 11 percent in the two placebo groups

    What this does not mean: Nausea and vomiting still lead the side effects. The 12.5 percent placebo figure came from a separate 12-week diabetes study (PMID 37311722).

    Peptides: Danuglipron

    Source: ClinicalTrials.gov NCT04707313, phase 2b dose-ranging study of danuglipron (PF-06882961) in adults with obesity, posted results (published as Buckeridge et al. 2025, PMID 40539310) (opens in a new tab) · Saved copy

  38. Evidence

    Corrected Oct 17, 2026: CJC-1295 + ipamorelin's scientific confidence is now weak, not moderate; human CJC-1295 trials used DAC, per PubMed (PMID 16352683).

    Before: moderate After: weak

    What this does not mean: No new study was published, and the dose tiers are unchanged. Ipamorelin has its own human studies. PubMed lists no trial of this blend or of CJC-1295 without DAC.

    Peptides: CJC-1295 + Ipamorelin

    Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  39. Dosing

    Corrected Oct 17, 2026: ARA-290's 2 mg daily tier now notes that no trial gave that dose; the dose-ranging trial used 1, 4 and 8 mg a day, per NCT02039687.

    Before: Moderate 2 mg daily, no note After: Moderate 2 mg daily, with a note: no trial gave 2 mg daily; daily SC trials used 1, 4 and 8 mg (Culver 2017) or 4 mg (Dahan 2013)

    What this does not mean: The tier value is unchanged; only a note was added. In that trial, 4 mg a day was the arm that met the primary endpoint (Culver 2017).

    Peptides: ARA-290

    Source: ClinicalTrials.gov NCT02039687, phase 2 dose-ranging study of ARA 290 in sarcoidosis (1, 4 or 8 mg a day for 28 days; published as Culver et al. 2017) (opens in a new tab) · Saved copy

  40. Evidence

    Corrected Oct 17, 2026: AOD-9604's human side effects now cite the six sponsor trials, not mouse and rat studies, per FDA's December 2024 PCAC briefing.

    Before: Credited oral-trial adverse events to PMID 10950816 and 11146367 (a mouse study and a rat study) and said all six trials were oral After: Cites the six human trials summarized by Stier 2013 (about 900 adults; four oral, two single IV): headache most common, adverse events similar to placebo

    What this does not mean: No new study was published. Two of the six trials gave single IV doses, so the page no longer says every trial was oral. No human study has tested subcutaneous injection.

    Peptides: AOD-9604

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for AOD-9604-related bulk drug substances, December 4, 2024 (memo dated November 5, 2024): the six sponsor trials summarized by Stier et al. 2013, two IV and four oral (pp. 32-35) (opens in a new tab) · Saved copy

  41. Safety

    Added Oct 17, 2026: AOD-9604's 12-week oral trial had serious adverse events, cancers among them, judged unrelated by its investigator, per FDA's 2024 briefing.

    Before: Listed headache and digestive events from the human trials and no serious adverse events After: Adds the 12-week trial's five serious adverse events (basal cell and squamous cell carcinoma, a lipoma, breast cancer, malignant melanoma), judged unrelated by the investigator, FDA could not assess relatedness; plus events judged possibly related in two smaller trials (diarrhea at 54 mg oral, severe chest tightness at 50 mcg/kg IV, euphoria)

    What this does not mean: No new study was published; the serious-event data come from Stier 2013's summary of the sponsor trials, via FDA in 2024. FDA found too little detail to judge whether the cancers were related. No human study tested subcutaneous use.

    Peptides: AOD-9604

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for AOD-9604-related bulk drug substances, December 4, 2024 (memo dated November 5, 2024): adverse events in the six sponsor trials summarized by Stier et al. 2013 (pp. 34-35) and FDA's caveat on them (p. 36) (opens in a new tab) · Saved copy

  42. Safety

    Corrected Oct 17, 2026: ACTH now carries the Acthar Gel section 4 contraindications, including intravenous use, live vaccines and peptic ulcer, per the label.

    Before: Peptic ulcer and osteoporosis as cautions; no intravenous, infants under 2, live vaccine, ocular herpes simplex, recent surgery, adrenocortical hyperfunction or porcine protein item After: The label section 4 list: intravenous use, infants under 2 with suspected congenital infections, live vaccines, scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction and porcine protein sensitivity

    What this does not mean: Doses and indications did not change. Cortrophin Gel lists all but the infant and live-vaccine lines. The page had called peptic ulcer and osteoporosis cautions and omitted intravenous use, live vaccines and recent surgery.

    Peptides: ACTH (Cosyntropin/Cortrosyn)

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  43. Safety

    Corrected Oct 16, 2026: SS-31 pregnancy risk is unknown, not contraindicated; allergy and newborn benzyl alcohol warnings added, per the FORZINITY label.

    Before: No reproductive safety data exists; SS-31 contraindicated in pregnancy and breastfeeding; no allergic reaction warning; benzyl alcohol called no concern for adults; eosinophilia said to clear by week 16 to 20 After: Not a label contraindication: no human pregnancy data, no harm in rat and rabbit studies (8.1), breastfeeding weighed against need (8.2); the section 5.1 and 5.2 warnings stated; eosinophil counts back to baseline after 6 to 12 months of use or after stopping (6.1)

    What this does not mean: There are still no human pregnancy data, so the risk is unknown. The page had said no reproductive data existed; rat and rabbit studies found no harm to development (section 8.1).

    Peptides: SS-31 (Elamipretide)

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  44. Dosing

    Corrected Oct 16, 2026: FORZINITY is a ready 80 mg/mL solution, so its 40 mg dose is 0.5 mL drawn with nothing mixed in, per the FORZINITY label.

    Before: Aggressive 40 mg daily, the FORZINITY label dose, with no note on its form beside the vial and BAC water math After: Aggressive 40 mg daily, noted as the FORZINITY label dose: a ready 80 mg/mL solution, 0.5 mL drawn from the vial with nothing added

    What this does not mean: FORZINITY's label did not change. The 4, 10 and 40 mg tiers are unchanged, and the calculator's vial and BAC water math still applies to research-grade powder only.

    Peptides: SS-31 (Elamipretide)

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  45. Safety

    Corrected Oct 16, 2026: serious hypersensitivity is the one label contraindication; pregnancy (risk unknown) and severe renal impairment are not, per FORZINITY.

    Before: Pregnancy or breastfeeding listed as contraindicated for lack of reproductive safety data, severe renal impairment listed as a contraindication, and known hypersensitivity After: Serious hypersensitivity, the one label contraindication (sections 4 and 5.2); pregnancy and breastfeeding per sections 8.1 and 8.2; severe renal impairment as the half dose of sections 2.2 and 8.6

    What this does not mean: Pregnancy risk is still unknown, since there are no human data; rat and rabbit studies found no harm. Severe renal impairment halves the label dose to 20 mg. Research-grade powder has no safety testing of its own.

    Peptides: SS-31 (Elamipretide)

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  46. EvidenceCorrected Oct 17, 2026

    Corrected Oct 16, 2026: sermorelin's scientific evidence is now rated moderate, not strong, after a re-read of its cited human trials, per PubMed.

    Before: strong After: moderate

    What this does not mean: Doses, safety grade and FDA history did not change. The cited human data is small: 19 older adults on a GHRH analog in 1997, 10 older men for 14 days in 1992, and GH-deficient children.

    Peptides: Sermorelin

    Source: Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. PMID 9141536 (opens in a new tab) · Archived snapshot (opens in a new tab)

  47. Safety

    Corrected Oct 16, 2026: in older adults, 16 weeks of twice-daily hexarelin lowered the cortisol response, not the prolactin response, per Rahim 1999.

    Before: At 300 mcg twice daily the cumulative cortisol burden becomes clinically meaningful; at higher twice-daily doses prolactin can rise enough to affect libido After: In older adults on 1.5 mcg/kg twice daily for 16 weeks the cortisol response fell and the prolactin response did not change (PMID 10341859); higher-dose symptoms labelled community reports

    What this does not mean: Hexarelin still raises cortisol, ACTH and prolactin after each injection. The 300 mcg twice daily protocol lacks long-term data, and community reports of poor sleep at that dose stay on the page.

    Peptides: Hexarelin

    Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  48. Safety

    Corrected Oct 16, 2026: hexarelin raises prolactin, ACTH and cortisol by about as much as GHRP-2 at equal doses, not more, per Arvat 1997.

    Before: Cortisol and prolactin rises more pronounced than with any other GHRP; Popovic's group confirmed this against GHRP-2 at equivalent doses (PMID 9285939) After: Community reports rank hexarelin worst for both; in Arvat's two small studies, prolactin, ACTH and cortisol rose by similar amounts with hexarelin and GHRP-2 at equal IV doses (PMID 9285939, 10195374)

    What this does not mean: Hexarelin still raises prolactin, ACTH and cortisol. The page had credited this paper to Popovic 1995. Human head-to-head data against GHRP-6 or ipamorelin on these hormones are lacking.

    Peptides: Hexarelin

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  49. Safety

    Corrected Oct 16, 2026: the hexarelin + GHRP-2 warning no longer says hexarelin has the highest cortisol and prolactin rise of any GHRP, per Arvat 1997.

    Before: Hexarelin already has the highest binding affinity and cortisol/prolactin elevation of any GHRP After: Hexarelin already has the highest binding affinity of any GHRP; at equal doses it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939)

    What this does not mean: Stacking hexarelin with GHRP-2 is still advised against. Both bind GHS-R1a, add no GH benefit together, and raise cortisol and prolactin.

    Peptides: Hexarelin

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  50. Safety

    Corrected Oct 16, 2026: GHRP-6's prolactin rise is no longer ranked below hexarelin's; the human head-to-head tests used GHRP-2, per Arvat 1997.

    Before: Prolactin elevation also occurs, more so than with ipamorelin but less than hexarelin After: Prolactin elevation also occurs, more so than with ipamorelin

    What this does not mean: GHRP-6 still raises prolactin, ACTH and cortisol. Human head-to-head data against hexarelin on these hormones are lacking.

    Peptides: GHRP-6

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  51. Safety

    Corrected Oct 16, 2026: oral and intranasal GHRP-6 left cortisol unchanged, per Frieboes 1999; the IV rise the page credited to it is from 1995.

    Before: GHRP-6 mildly raises ACTH and cortisol, confirmed by Frieboes and colleagues in their neuroendocrine study (PMID 10336729) After: IV GHRP-6 raised ACTH and cortisol (PMID 7617137); oral and intranasal GHRP-6 left cortisol unchanged (PMID 10336729)

    What this does not mean: GHRP-6 still raises ACTH and cortisol after IV doses (PMID 7617137). This moves a citation; it is not a new safety finding.

    Peptides: GHRP-6

    Source: J Neuroendocrinol 1999, Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration (Frieboes et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  52. Safety

    Corrected Oct 16, 2026: GHRP-6's cumulative cortisol load claim is gone; 16 weeks of hexarelin in older adults lowered the cortisol response, per Rahim 1999.

    Before: At 200 to 300 mcg three times daily, the cumulative cortisol load becomes meaningful enough to potentially impair recovery, sleep quality, and fat metabolism After: Long-term cortisol data for GHRP-6 are lacking; in older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)

    What this does not mean: GHRP-6 still raises ACTH and cortisol after IV doses. Long-term cortisol data for GHRP-6 itself are lacking, and the week-four morning cortisol check on aggressive protocols stays.

    Peptides: GHRP-6

    Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  53. Safety

    Corrected Oct 16, 2026: GHRP-2 raises prolactin by about as much as hexarelin at equal doses, not less, per Arvat 1997.

    Before: The prolactin burden is lower than hexarelin but higher than ipamorelin After: The prolactin burden is similar to hexarelin's at equal doses (PMID 9285939) but higher than ipamorelin's

    What this does not mean: GHRP-2 still raises prolactin, ACTH and cortisol. The comparison with ipamorelin is unchanged.

    Peptides: GHRP-2

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  54. Safety

    Corrected Oct 16, 2026: GHRP-2's cumulative cortisol burden claim is gone; 16 weeks of hexarelin in older adults lowered the cortisol response, per Rahim 1999.

    Before: At three times daily advanced protocols, cumulative cortisol burden can become clinically relevant After: Long-term cortisol data for GHRP-2 are lacking; in older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)

    What this does not mean: GHRP-2 still raises ACTH, cortisol and prolactin after each injection. Long-term cortisol data for GHRP-2 itself are lacking, and the AM cortisol check on the advanced protocol stays.

    Peptides: GHRP-2

    Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  55. Safety

    Corrected Oct 16, 2026: the GHRP-2 + hexarelin warning no longer says hexarelin has the highest cortisol and prolactin rise of any GHRP, per Arvat 1997.

    Before: Hexarelin already produces the highest cortisol and prolactin elevation of any GHRP After: At equal doses, hexarelin and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939)

    What this does not mean: Stacking GHRP-2 with hexarelin is still advised against. Both bind GHS-R1a, add no documented GH benefit together, and raise cortisol and prolactin.

    Peptides: GHRP-2

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  56. Evidence

    Corrected Oct 16, 2026: CJC-1295 + ipamorelin now reads Limited Research; the human CJC-1295 trials used the DAC form, per PubMed (PMID 16352683).

    Before: well-researched After: limited-research

    What this does not mean: Ipamorelin has its own human studies, and the dose tiers are unchanged. PubMed lists no trial of this blend or of CJC-1295 without DAC.

    Peptides: CJC-1295 + Ipamorelin

    Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  57. Safety

    Corrected Oct 15, 2026: tesamorelin side effects no longer say neutralizing antibodies blunt fat loss; responses were comparable, per the EGRIFTA SV label.

    Before: A subset of 10 to 15% develop neutralizing antibodies that blunt the VAT response; cycling 26 weeks on, 4 to 8 weeks off, restores it After: Antibodies in 50% at 26 weeks and 47% at 52 weeks; neutralizing in 10% at week 52, with comparable VAT and IGF-1 changes (label section 12.6)

    What this does not mean: Antibodies still formed in about half of trial patients, and in 85% of those with hypersensitivity reactions. Community protocols may still take breaks; the label gives no antibody reason for them.

    Peptides: Tesamorelin

    Source: EGRIFTA SV (tesamorelin) prescribing information, section 12.6 Immunogenicity (openFDA label record, SPL version 9, effective Jul 29, 2026) (opens in a new tab) · Saved copy

  58. Evidence

    Corrected Oct 15, 2026: TB-500's side effects no longer cite one 'only' phase 1 trial; no study has given TB-500 itself to people, per FDA's TB-500 briefing.

    Before: Called PMID 34346165 the only published phase 1, in 36 volunteers, and said TB-500 had never completed a phase 2 or 3 trial After: No published study has given TB-500 to people; two phase 1 trials of full-length thymosin beta-4 (40 volunteers, PMID 20536472; 54 plus 30, PMID 34346165)

    What this does not mean: No new study was published. Two phase 1 trials (Ruff 2010, PMID 20536472; Wang 2021, PMID 34346165) gave intravenous full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment.

    Peptides: TB-500

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for TB-500-related bulk drug substances, July 23-24, 2026 (memo dated May 15, 2026): 'FDA is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA' (p. 32) (opens in a new tab) · Saved copy

  59. Evidence

    Corrected Oct 15, 2026: ipamorelin's only published human RCT is Beck 2014; a second, 320-patient Phase 2 trial ended without results, per ClinicalTrials.gov.

    Before: The only completed human RCT (Phase 2b, postoperative ileus, approximately 100 participants) After: The only published human RCT (Phase 2, 117 adults after bowel resection, PMID 25331030); a second Phase 2 trial (NCT01280344, 320 patients) finished in 2014 without posted results

    What this does not mean: Both trials gave ipamorelin intravenously after bowel surgery; neither tested subcutaneous use. Dose tiers on this page are unchanged.

    Peptides: Ipamorelin

    Source: ClinicalTrials.gov NCT01280344, Phase 2 dose-finding trial of ipamorelin vs. placebo for GI recovery after bowel resection (320 enrolled, completed May 2014, no results posted; last update posted Apr 13, 2017) (opens in a new tab) · Saved copy

  60. Regulatory

    Corrected Oct 15, 2026: somatropin's status section drops the 1985 date, the biosimilar claim and the kidney-disease indication, per FDA's biosimilar list.

    What this does not mean: Somatropin's FDA approval is unchanged. FDA's biosimilar list (content current Oct 5, 2026) names no somatropin, so Omnitrope is not a US biosimilar. Nutropin AQ, the kidney-disease brand, is no longer licensed.

    Peptides: HGH (Somatropin)

    Source: FDA, Biosimilar Product Information (content current as of 10/05/2026): no somatropin product or somatropin reference product is listed (opens in a new tab) · Saved copy

  61. Regulatory

    Corrected Oct 15, 2026: somatropin's US status now lists its licensed BLAs and marks Saizen and Nutropin AQ revoked, per FDA's Purple Book.

    Before: No sourced US status record After: FDA-approved (licensed biologic): Norditropin BLA 021148, Genotropin BLA 020280, Humatrope BLA 019640, Omnitrope BLA 021426, Zomacton BLA 019774, Serostim BLA 020604 licensed; Saizen BLA 019764 and Nutropin AQ BLA 020522 voluntarily revoked

    What this does not mean: No approval changed. Somatropin stays a licensed biologic with the same labels; the revoked brands left the market earlier. Compounded somatropin is not a licensed product.

    Peptides: HGH (Somatropin)

    Source: FDA Purple Book, monthly data download, September 2026 (BLA 021148 Norditropin, 020280 Genotropin, 019640 Humatrope, 021426 Omnitrope, 019774 Zomacton, 020604 Serostim: Rx, Licensed; 019764 Saizen and 020522 Nutropin AQ: Disc, Voluntarily Revoked) (opens in a new tab) · Saved copy

  62. Safety

    Corrected Oct 15, 2026: somatropin side effects now list the label contraindications and the intracranial hypertension warning, per the Norditropin label.

    Before: Pregnancy listed as a contraindication; no intracranial hypertension warning; edema up to 45%; carpal tunnel 1-10%; gynecomastia rare; Swedish HR 1.28 called benign-only After: Label contraindications in full, pregnancy a caution; IH warning added; edema 42% vs 8%; carpal tunnel 2% (GHD) and 7-50% (anti-aging trials); gynecomastia 7-14%; HR 1.28 all neoplasms

    What this does not mean: Not a new finding. Edema shows 42% vs 8% on placebo (Norditropin label). Carpal tunnel shows 2% in GH-deficient adults and 7-50% in anti-aging trials. HR 1.28 covers all neoplasms.

    Peptides: HGH (Somatropin)

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  63. Safety

    Corrected Oct 15, 2026: somatropin's glucocorticoid interaction now says replacement doses may need to rise, per the Norditropin label.

    Before: Glucocorticoid line twice; CYP450 examples theophylline, cyclosporine, warfarin; somatostatin said to block GH receptor signaling and fully negate HGH After: 11β-HSD1 point with higher replacement or stress doses; high-dose steroids blunt growth in children; label CYP450 examples; somatostatin analogs work against HGH

    What this does not mean: No interaction was dropped. A repeated glucocorticoid line now gives the label's pediatric growth point, and the somatostatin line loses an unsourced receptor claim.

    Peptides: HGH (Somatropin)

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  64. Safety

    Corrected Oct 15, 2026: somatropin contraindications now give the label's Prader-Willi criteria and list pregnancy as a caution, per the Norditropin label.

    Before: Prader-Willi syndrome with severe obesity or respiratory impairment (pediatric); pregnancy or breastfeeding as a contraindication, Category B/C After: Children with Prader-Willi syndrome who are severely obese or have airway obstruction, sleep apnea or severe respiratory impairment; pregnancy a label caution

    What this does not mean: Pregnancy stays on the list as a caution; labels call the human data too limited to judge. The other five contraindications are unchanged.

    Peptides: HGH (Somatropin)

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  65. Regulatory

    Corrected Oct 15, 2026: dermorphin's status section no longer calls it a Schedule I analog; it is unscheduled, with no application listed, per Drugs@FDA.

    What this does not mean: The Analogue Act can still reach an unscheduled substance sold for human use. No DEA statement or court ruling applying it to dermorphin was found (eCFR part 1308 and the DEA list, Oct 15, 2026).

    Peptides: Dermorphin

    Source: Drugs@FDA (openFDA) search for active ingredient DERMORPHIN: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy

  66. Regulatory

    Corrected Oct 15, 2026: dermorphin now carries a sourced US status: none listed in Drugs@FDA and no federal schedule, per Drugs@FDA and the DEA list.

    Before: No sourced US status record After: Unapproved in the US; no application in Drugs@FDA; absent from 21 CFR 1308 and the DEA controlled substances list (Aug 27, 2026)

    What this does not mean: Unscheduled does not make it lawful to sell for human use: in 2017 a federal jury convicted a veterinarian and a pharmacy under the Food, Drug, and Cosmetic Act for selling it for race horses.

    Peptides: Dermorphin

    Source: Drugs@FDA (openFDA) search for active ingredient DERMORPHIN: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy

  67. Regulatory

    Corrected Oct 15, 2026: bromantane's status section drops the state-legality claim and the IND wording; no application for it is listed, per Drugs@FDA.

    What this does not mean: Nothing changed at FDA. IND filings are not public, so the old 'no active IND' line could not be checked, and no state-by-state survey backed the purchase claim.

    Peptides: Bromantane (Ladasten)

    Source: Drugs@FDA (openFDA) search for active ingredient BROMANTANE: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy

  68. Regulatory

    Corrected Oct 15, 2026: bromantane now carries a sourced US status: no US application in Drugs@FDA and no federal schedule, per Drugs@FDA.

    Before: No sourced US status record After: Unapproved in the US; no application in Drugs@FDA; absent from 21 CFR 1308, the DEA list and the 503A and 503B category lists

    What this does not mean: Russian registration as Ladasten stays in the page text only; its state-register record is not captured. Nothing changed at FDA or DEA, and WADA still lists it as a non-specified stimulant (S6.A).

    Peptides: Bromantane (Ladasten)

    Source: Drugs@FDA (openFDA) search for active ingredient BROMANTANE: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy

  69. Safety

    Corrected Oct 15, 2026: Bromantane's side effects now say WADA lists it as a non-specified stimulant (S6.A), prohibited in competition, per WADA's 2026 list.

    Before: Called bromantane a specified stimulant under category S6 After: Non-specified stimulant (S6.A) on the 2026 Prohibited List, prohibited in competition

    What this does not mean: WADA did not reclassify bromantane in 2026. The page named the wrong S6 subclass and said it was prohibited out of competition too; S6 applies in competition only.

    Peptides: Bromantane (Ladasten)

    Source: World Anti-Doping Agency, 2026 Prohibited List (in effect Jan 1, 2026), S6.A Non-Specified Stimulants (opens in a new tab) · Saved copy

  70. Safety

    Corrected Oct 15, 2026: Bromantane's athlete warning now gives WADA class S6.A, a non-specified stimulant prohibited in competition, per WADA's 2026 list.

    Before: Athletes item said bromantane is a specified stimulant on the Prohibited List (S6) After: Athletes item says non-specified stimulant on the 2026 Prohibited List (S6.A), prohibited in competition

    What this does not mean: The advice to athletes is unchanged: bromantane is on the Prohibited List. Only the subclass and the in-competition scope were corrected.

    Peptides: Bromantane (Ladasten)

    Source: World Anti-Doping Agency, 2026 Prohibited List (in effect Jan 1, 2026), S6.A Non-Specified Stimulants (opens in a new tab) · Saved copy

  71. Regulatory

    Corrected Oct 15, 2026: the Wolverine Stack now carries a sourced US status: none listed in Drugs@FDA, both components withdrawn from category 2, per FDA.

    Before: No sourced US status record After: Unapproved in the US; no application in Drugs@FDA; BPC-157 and TB-500 sit on FDA's nominated-but-withdrawn table, off the 503A bulks list

    What this does not mean: Nothing changed at FDA. Neither BPC-157 nor TB-500 is on the 503A bulks list, and no proposed or final rule adds either (Federal Register search, Oct 15, 2026).

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

  72. Evidence

    Corrected Oct 15, 2026: the Wolverine Stack's side effects no longer credit TB-500 with a phase 1 safety study; none has given it to people, per FDA.

    Before: TB-500 has one Phase I safety study (PMID 34346165) After: TB-500 itself has no published human safety data; two phase 1 trials gave intravenous full-length thymosin beta-4 (PMID 20536472, PMID 34346165)

    What this does not mean: The two phase 1 trials (PMID 20536472, PMID 34346165) tested intravenous full-length thymosin beta-4, the parent protein, not the TB-500 fragment in the blend. The BPC-157 line is unchanged.

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for TB-500-related bulk drug substances, July 23-24, 2026 (memo dated May 15, 2026): 'FDA is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA' (p. 32) (opens in a new tab) · Saved copy

  73. Evidence

    Corrected Oct 15, 2026: the Wolverine Stack serotonin line now cites a 2004 rat brain study, not a dopamine paper, per PubMed (PMID 15531385).

    Before: BPC-157 modulates serotonin and dopamine pathways (cited to PMID 9073154, an adrenergic and dopamine paper) After: In rats, BPC-157 interacts with dopamine and adrenergic systems (PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385)

    What this does not mean: The warning is unchanged. Anxiety and mood effects remain community reports, and the rat data only make them plausible. PMID 9073154 still backs the dopamine and adrenergic link.

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: Life Sci 2004, Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain (Tohyama, Sikiric and Diksic) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  74. Evidence

    Corrected Oct 15, 2026: the Wolverine Stack now reads Limited Research; the only controlled test of the pair was in rats, per Jt Dis Relat Surg (PMID 42542926).

    Before: well-researched After: limited-research

    What this does not mean: Dose tiers are unchanged. Each component has its own studies; no human trial has tested the pre-mixed blend, and 4 patients in one chart review got BPC-157 with thymosin beta-4.

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: Joint Diseases and Related Surgery 2026, BPC-157 and TB-500 on Achilles tendon healing in rats (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  75. Regulatory

    Corrected Oct 15, 2026: the Wolverine Stack page no longer calls BPC-157 and TB-500 "FDA-prohibited"; both left category 2, per FDA.

    What this does not mean: Neither peptide is on the 503A bulks list, so pharmacies still cannot compound them. No proposed or final rule exists (Federal Register search, Oct 15, 2026).

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

  76. Dosing

    Corrected Oct 15, 2026: the Wolverine Stack's top tier is now 1,000 mcg once a day, not 1,500 mcg twice a day; no human dose exists, per FDA's TB-500 briefing.

    Before: Aggressive 1,500 mcg total twice daily (3,000 mcg a day); post-op protocol 1,000 mcg twice daily; FAQ 500 mcg BPC-157 plus 1,000 mcg TB-500; none sourced After: Aggressive 1,000 mcg total once daily, equal to moderate (the community ceiling); the post-op protocol, guide, benefits and FAQ cap at 1,000 mcg a day, labelled community reports

    What this does not mean: The beginner and moderate tiers are unchanged; the top tier now equals moderate. 1,000 mcg a day is a community figure, not a studied dose. FDA found no human data for TB-500.

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for TB-500-related bulk drug substances, July 23-24, 2026 (memo dated May 15, 2026): 'FDA is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA' (p. 32) (opens in a new tab) · Saved copy

  77. Dosing

    Corrected Oct 14, 2026: kisspeptin-10 IV bolus doses in men were 0.01 to 3.0 mcg/kg, with the largest LH rise at 1 mcg/kg, per PubMed (PMID 21632807).

    What this does not mean: The dose tiers on this page are unchanged. These were IV boluses dosed per kilogram in healthy men, not subcutaneous community doses.

    Peptides: Kisspeptin-10

    Source: J Clin Endocrinol Metab 2011, Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  78. Dosing

    Corrected Oct 14, 2026: the CJC-1295 trials dosed per kilogram with the DAC form, best tolerated at 30 or 60 mcg/kg, per PubMed (PMID 16352683).

    What this does not mean: The dose tiers on this page are unchanged. The page had listed trial doses as 30 to 300 mcg, which mixed per-kilogram doses with flat community doses.

    Peptides: CJC-1295 + Ipamorelin

    Source: J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  79. Safety

    Corrected Oct 14, 2026: Gattex has no boxed warning; the teduglutide side effects now follow its five label warnings and trial rates, per the Gattex label.

    Before: A "boxed-style warning" for neoplastic growth, teratogenic effects in animal studies, stopping for any cancer, headache in about 35% and a nephrolithiasis signal After: No boxed warning. The five section 5 warnings (neoplastic growth, obstruction, biliary and pancreatic disease, fluid overload, oral drug absorption), label trial rates, stopping for GI cancers

    What this does not mean: The tumor-growth warning stands, with screening before and during treatment. The side effects had cited birth defects in animals (the label found no embryo-fetal harm), a kidney stone signal and a 35% headache rate; the label gives none.

    Peptides: Teduglutide (Gattex/Revestive)

    Source: Gattex (teduglutide) prescribing information (openFDA label record, SPL version 20, effective Sep 5, 2025) (opens in a new tab) · Saved copy

  80. Safety

    Corrected Oct 14, 2026: Gattex lists no contraindications; the teduglutide list now carries its warnings and no animal birth-defect claim, per the Gattex label.

    Before: Active GI cancer listed as a contraindication, a 5-year GI cancer history rule, known hypersensitivity, and "teratogenic effects observed in animal studies" for pregnancy After: No label contraindications. Section 5 warnings (stop for GI cancer, polyps, obstruction, biliary and pancreatic disease, fluid overload), no embryo-fetal harm in animals, breastfeeding not recommended

    What this does not mean: Stopping for a GI cancer, polyp removal before starting and the lab checks still apply as label warnings. The list had called GI cancer a contraindication and added a 5-year cancer rule and a hypersensitivity line.

    Peptides: Teduglutide (Gattex/Revestive)

    Source: Gattex (teduglutide) prescribing information (openFDA label record, SPL version 20, effective Sep 5, 2025) (opens in a new tab) · Saved copy

  81. Safety

    Corrected Oct 14, 2026: retatrutide side effects now give TRIUMPH-2 stop rates, 8 to 12% on 9 and 12 mg vs 5% on placebo, per The Lancet.

    Before: No discontinuation rates; said Phase 3 data suggest the heart rate rise is manageable; said no reproductive toxicity data exist After: TRIUMPH-2 stop rates (12% on 9 mg, 8% on 12 mg vs 5%) and TRIUMPH-4 topline rates added; no heart rate figures in the TRIUMPH-1 and -2 abstracts; no published pregnancy data

    What this does not mean: No new signal. The page also drops a claim that Phase 3 showed the heart rate rise is manageable; the TRIUMPH-1 and TRIUMPH-2 abstracts give no heart rate figures.

    Peptides: Retatrutide

    Source: Lancet 2026, Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  82. Safety

    Corrected Oct 14, 2026: liraglutide with insulin or a sulfonylurea may call for a lower dose of that drug, not a do-not-combine, per the Victoza label.

    What this does not mean: The risk is real: hypoglycemia, including severe hypoglycemia. Victoza says to consider a lower insulin or sulfonylurea dose when starting (section 7.2). Saxenda adds glucose checks in type 2 diabetes (section 5.4).

    Peptides: Liraglutide

    Source: Victoza (liraglutide) prescribing information (openFDA label record, SPL version 31, effective Oct 14, 2025; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

  83. Safety

    Corrected Oct 14, 2026: kisspeptin-10's side effects now cite its FDA 503A Category 2 listing since Sep 29, 2023, per FDA.

    Before: FDA Pharmacy Compounding Advisory Committee rejected kisspeptin for compounding in October 2024; tachyphylaxis study described as daily kisspeptin-54 After: In FDA 503A Category 2 since Sep 29, 2023 (FDA Category 2 page captured Oct 6, 2026); tachyphylaxis study described as twice-daily kisspeptin-54 injections

    What this does not mean: No new safety finding. FDA's advisory committee voted 0 to 11 against kisspeptin-10 on Oct 29, 2024, but FDA has not ruled on the 503A bulks list. The cited study used twice-daily kisspeptin-54.

    Peptides: Kisspeptin-10

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

  84. Dosing

    Corrected Oct 14, 2026: somatropin's adult GHD protocol now starts at 0.15 to 0.3 mg a day, not 0.1 to 0.2 mg, per the Norditropin label.

    What this does not mean: The old range began at 0.1 mg, below the label's 0.15 mg floor, and held for 12 weeks before any step. Community dose tiers are unchanged, and the label sets no fixed maintenance dose.

    Peptides: HGH (Somatropin)

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  85. Safety

    Corrected Oct 14, 2026: HGH side effects now list the label contraindications and the intracranial hypertension warning, per the Norditropin label.

    Before: Contraindications paragraph called cancer history and pregnancy or breastfeeding absolute stop signs; no intracranial hypertension warning After: Label contraindications listed in full; a past cancer must be inactive and treated first; pregnancy data too limited; intracranial hypertension warning added

    What this does not mean: No new risk. Past cancer and pregnancy stay on the page as label cautions; the labels contraindicate active malignancy and call pregnancy data too limited to judge.

    Peptides: HGH 191AA

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  86. Dosing

    Corrected Oct 14, 2026: HGH's adult GHD protocol now starts at 150 to 300 mcg a day, not 33 to 167 mcg, per the Norditropin label.

    What this does not mean: The old protocol read a 0.1 to 0.5 mg range as IU, a third of the intended dose. The calculator tiers (200, 500 and 1,000 mcg) are unchanged.

    Peptides: HGH 191AA

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  87. Safety

    Corrected Oct 14, 2026: HGH's glucocorticoid interaction now says replacement doses may need to rise, per the Norditropin label.

    Before: Glucocorticoids (prednisone, hydrocortisone) may reduce GH efficacy; somatostatin line said it opposes HGH's receptor activity After: GH inhibits 11β-HSD1 and can unmask adrenal insufficiency; anyone on glucocorticoid replacement may need higher maintenance or stress doses, cortisone acetate and prednisone most; somatostatin analogs work against HGH

    What this does not mean: No interaction was removed. The somatostatin analog line was reworded to fix a display error and drop an unsourced receptor claim.

    Peptides: HGH 191AA

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  88. Dosing

    Corrected Oct 14, 2026: HGH 191AA's summary, dosage FAQ and consensus note now give the adult GHD label start, 0.45 to 0.9 IU a day, per the Norditropin label.

    What this does not mean: The 0.3 to 1.5 IU range stays, labelled as AACE 2019 guideline starting doses by age. The calculator tiers (200, 500 and 1,000 mcg) are unchanged.

    Peptides: HGH 191AA

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  89. Safety

    Corrected Oct 14, 2026: HGH contraindications now follow the label, with past cancer and pregnancy as cautions, per the Norditropin label.

    Before: Active malignancy or history of cancer; Prader-Willi syndrome with severe obesity or respiratory impairment; pregnancy or breastfeeding, each a contraindication After: Active malignancy (past cancer inactive and treated first); children with Prader-Willi syndrome at obesity, airway or breathing risk; pregnancy as a label caution

    What this does not mean: Both cautions stay listed. Active malignancy remains a contraindication, and a past cancer must be inactive and fully treated before starting.

    Peptides: HGH 191AA

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  90. Safety

    Corrected Oct 14, 2026: CJC-1295 + ipamorelin side effects now list serious events, including raised heart rate and a death in an IV ipamorelin study, per FDA.

    Before: Flushing called common and benign; CJC-1295 said to have Phase I/II data; ipamorelin tolerability credited to Johansen 1999 and Raun 1998 After: Flushing reported as common in the community; FDA-cited serious events for CJC-1295 and IV ipamorelin listed; human CJC-1295 data credited to the DAC form; ipamorelin PK credited to Gobburu 1999

    What this does not mean: No new study. FDA's Category 2 page holds this text; FDA words them as 'associated with' and says clinical data are limited. Human CJC-1295 data come from the DAC form; the No DAC form in this blend has no published human trial.

    Peptides: CJC-1295 + Ipamorelin

    Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy

  91. Safety

    Corrected Oct 14, 2026: CCK-8 may cause preterm labor or miscarriage, a label warning, and an infusion eases its GI effects, per the Kinevac label.

    Before: Pregnancy is contraindicated (preterm labor, spontaneous abortion); a 30 to 50 minute infusion and a dilution step presented as required After: Pregnancy: label warning of preterm labor or spontaneous abortion (5.4, 8.1); the label offers an infusion to reduce GI effects (5.3)

    What this does not mean: Pregnancy still carries the warning (sections 5.4 and 8.1). The page had called pregnancy a contraindication and blamed failed protocols on a skipped dilution step; the label says neither.

    Peptides: Cholecystokinin (CCK-8)

    Source: Kinevac (sincalide) prescribing information (openFDA label record, SPL version 13, effective Oct 18, 2023; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

  92. Safety

    Corrected Oct 14, 2026: pregnancy is a label warning for CCK-8 (sincalide), not a contraindication, per the Kinevac label, sections 4, 5.4 and 8.1.

    Before: Pregnancy (risk of preterm labor and spontaneous abortion due to smooth muscle stimulation) After: Pregnancy: not a label contraindication, but the Kinevac label warns of preterm labor or spontaneous abortion (sections 5.4 and 8.1)

    What this does not mean: Sincalide may cause preterm labor or spontaneous abortion, so pregnancy stays on the list as a warning. The label contraindications are sulfite or sincalide hypersensitivity and intestinal obstruction.

    Peptides: Cholecystokinin (CCK-8)

    Source: Kinevac (sincalide) prescribing information (openFDA label record, SPL version 13, effective Oct 18, 2023; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

  93. Safety

    Corrected Oct 13, 2026: the exenatide 1-hour rule covers threshold drugs such as antibiotics, not warfarin; check INR more often instead, per the Byetta label.

    Before: Oral narrow-TI drugs (warfarin, digoxin, levothyroxine): take these medications ≥1 hour before exenatide injection After: No dose timing for warfarin or digoxin. With warfarin, check INR more often after starting or changing exenatide. Digoxin Cmax fell 17% with AUC unchanged. The 1-hour rule covers threshold drugs such as antibiotics

    What this does not mean: Antibiotics and oral contraceptives still go at least 1 hour before Byetta. Digoxin Cmax fell 17% with AUC unchanged. Neither label names levothyroxine.

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  94. Safety

    Corrected Oct 13, 2026: semaglutide side effects now use label figures, including 22% dysesthesia on 7.2 mg, not 18.9%, per the Wegovy label.

    Before: Dysesthesia 18.9% on 7.2 mg vs 0% placebo; 26% of SELECT participants had heart rate rises of 20 bpm or more; constipation affects the majority; three signals dated to a September 2023 warning; pancreatitis history, pregnancy, breastfeeding and gastroparesis listed as contraindications After: Dysesthesia 22% on 7.2 mg vs 6% on 2.4 mg and 0.3% placebo; 26% vs 16% had rises of 20 bpm or more in the weight trials; constipation 24% vs 11%; label contraindications are MTC or MEN 2 history and serious hypersensitivity, with the rest as label cautions

    What this does not mean: No new risk. The 26% heart rate figure comes from the weight trials, not SELECT, and the label does not date the ileus listing to September 2023.

    Peptides: Semaglutide

    Source: Wegovy (semaglutide) injection and tablets prescribing information, NDA 215256 supplement 025, revised 06/2026 (Drugs@FDA label; captured as the same-text DailyMed SPL version 19, effective Jun 18, 2026) (opens in a new tab) · Saved copy

  95. Safety

    Corrected Oct 13, 2026: semaglutide did not change ethinyl estradiol or levonorgestrel exposure, and no backup contraception is advised, per the Wegovy label.

    Before: Additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: Label studies found no clinically significant change in ethinyl estradiol or levonorgestrel exposure; the Wegovy label calls for no backup contraception

    What this does not mean: The tirzepatide and orforglipron labels do call for backup contraception after starts and dose increases. Semaglutide still slows gastric emptying, so narrow-margin oral drugs need monitoring.

    Peptides: Semaglutide

    Source: Wegovy (semaglutide) injection and tablets prescribing information, NDA 215256 supplement 025, revised 06/2026 (Drugs@FDA label; captured as the same-text DailyMed SPL version 19, effective Jun 18, 2026) (opens in a new tab) · Saved copy

  96. Safety

    Corrected Oct 13, 2026: pancreatitis history, pregnancy, breastfeeding and gastroparesis now read as label cautions for semaglutide, per the Wegovy label.

    Before: History of pancreatitis; pregnancy or breastfeeding; severe gastrointestinal disease (e.g., gastroparesis), each listed as a contraindication After: Each kept with its label status: pancreatitis history is not a label contraindication; stop in pregnancy, no breastfeeding on Wegovy tablets; severe gastroparesis is not recommended

    What this does not mean: The cautions stay on the page. The label contraindicates only MTC or MEN 2 history and serious hypersensitivity, and says to stop in pregnancy and 2 months before a planned one.

    Peptides: Semaglutide

    Source: Wegovy (semaglutide) injection and tablets prescribing information, NDA 215256 supplement 025, revised 06/2026 (Drugs@FDA label; captured as the same-text DailyMed SPL version 19, effective Jun 18, 2026) (opens in a new tab) · Saved copy

  97. Safety

    Corrected Oct 13, 2026: orforglipron caused no rodent thyroid tumors; its boxed warning is the GLP-1 class warning, per the Foundayo label.

    Before: Thyroid C-cell tumors developed in rodent studies at clinically relevant exposures; constipation 30%; GI discontinuation 3.5 to 10%; pregnancy called a contraindication After: Orforglipron is not active in rats or mice and caused no rodent tumors (class warning); constipation 20 to 27%; 3 to 6% stopped for GI side effects vs 0.7%; stop once pregnancy is recognized

    What this does not mean: The boxed warning and the MTC and MEN 2 contraindication stay, and human risk is unknown. The page also now gives label rates for constipation and for stopping over GI side effects.

    Peptides: Orforglipron

    Source: Foundayo (orforglipron) prescribing information (openFDA label record, SPL version 10, effective Jul 29, 2026) (opens in a new tab) · Saved copy

  98. Safety

    Corrected Oct 13, 2026: orforglipron is capped at 9 mg daily with strong CYP3A4 inhibitors, and strong inducers are to be avoided, per the Foundayo label.

    Before: CYP3A4 inhibitors: monitor closely; CYP3A4 inducers: may reduce efficacy; GLP-1 combinations called contraindicated per FDA label After: Strong CYP3A4 inhibitors: 9 mg daily cap, avoid those that also inhibit OATP1B; strong inducers: avoid (carbamazepine cut exposure 82%); GLP-1 combinations: not recommended per label

    What this does not mean: The dose tiers on this page are unchanged. Other GLP-1 drugs alongside it are not recommended on the label; the page had called the combination contraindicated.

    Peptides: Orforglipron

    Source: Foundayo (orforglipron) prescribing information (openFDA label record, SPL version 10, effective Jul 29, 2026) (opens in a new tab) · Saved copy

  99. Safety

    Corrected Oct 13, 2026: other GLP-1 drugs and pregnancy are label cautions for orforglipron, not contraindications, per the Foundayo label.

    Before: Concurrent use with other GLP-1 receptor agonists; pregnancy or planning to become pregnant (both listed as contraindications) After: Other GLP-1 receptor agonists: not recommended together (a limitation of use); pregnancy: stop once recognized (a label caution)

    What this does not mean: Do not combine it with another GLP-1 drug, and stop it once pregnancy is recognized. The label contraindicates MTC or MEN 2 history and serious hypersensitivity.

    Peptides: Orforglipron

    Source: Foundayo (orforglipron) prescribing information (openFDA label record, SPL version 10, effective Jul 29, 2026) (opens in a new tab) · Saved copy

  100. Evidence

    Corrected Oct 13, 2026: in ACHIEVE-3, 9 to 10% stopped orforglipron for side effects vs 4 to 5% on oral semaglutide, about double, per PubMed.

    Before: GI discontinuation about 4x higher than oral semaglutide in the ACHIEVE-3 comparison After: In ACHIEVE-3, 9 to 10% stopped orforglipron for side effects vs 4 to 5% on oral semaglutide (PMID 41765029)

    What this does not mean: The page had said about 4 times. Orforglipron still lowered HbA1c more than oral semaglutide in the same trial, and its pulse rise was larger (3.7 to 4.7 vs 1.0 to 1.5 bpm).

    Peptides: Orforglipron

    Source: Lancet 2026, Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  101. Safety

    Corrected Oct 13, 2026: lixisenatide calls for pill timing (at least 1 hour before or 11 hours after), not backup contraception, per the Adlyxin label.

    Before: Additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: The Adlyxin label calls for no backup contraception. A pill taken at least 1 hour before or 11 hours after the dose kept its normal levels

    What this does not mean: Taken 1 or 4 hours after a dose, pill hormone peaks fell 20 to 52% with no change in AUC, so the timing matters. The Soliqua 100/33 label gives the same timing.

    Peptides: Lixisenatide

    Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) (opens in a new tab) · Saved copy

  102. Safety

    Corrected Oct 13, 2026: liraglutide lowered pill hormone peaks 12 to 13% with no drop in AUC, and no backup contraception is advised, per the Saxenda label.

    Before: Oral contraceptives: Cmax reduced by 12%, take at least 1 hour before injection; additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: Cmax down 12% (ethinyl estradiol) and 13% (levonorgestrel), Tmax 1.5 hours later, AUC not lowered. The Saxenda and Victoza labels set no dose timing and call for no backup contraception

    What this does not mean: The page had said to take the pill 1 hour before the injection; that timing comes from the Byetta and Adlyxin labels. The tirzepatide and orforglipron labels do call for backup contraception.

    Peptides: Liraglutide

    Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) (opens in a new tab) · Saved copy

  103. Safety

    Corrected Oct 13, 2026: exenatide calls for pill timing (at least 1 hour before the injection), not backup contraception, per the Byetta label.

    Before: Additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: The Byetta label calls for no backup contraception. Take the pill at least 1 hour before the injection; taken 30 minutes after, Cmax fell 45% and 27%

    What this does not mean: The 1 hour timing stands. A pill taken 30 minutes after Byetta lost 45% (ethinyl estradiol) and 27% (levonorgestrel) of its peak level. The Bydureon BCise label sets no timing.

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  104. Safety

    Corrected Oct 13, 2026: dulaglutide 1.5 mg had no clinically relevant effect on tested oral drugs; no backup contraception is advised, per the Trulicity label.

    Before: Additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: The Trulicity label calls for no backup contraception. At 1.5 mg, the tested oral drugs (norelgestromin and ethinyl estradiol among them) were not affected to a clinically relevant degree

    What this does not mean: Dulaglutide still slows gastric emptying, so the label says to monitor narrow-margin drugs such as warfarin. Data at 3 mg and 4.5 mg are limited. The tirzepatide label does call for backup contraception.

    Peptides: Dulaglutide (Trulicity)

    Source: Trulicity (dulaglutide) prescribing information (openFDA label record, SPL version 62, effective Jun 16, 2026; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

  105. Evidence

    Corrected Oct 13, 2026: the BPC-157 serotonin line now cites a 2004 rat brain study, not a dopamine paper, per PubMed (PMID 15531385).

    Before: BPC-157 modulates both dopamine and serotonin systems in animal studies (cited to PMID 9073154, an adrenergic and dopamine paper) After: In rats, BPC-157 interacts with dopamine and adrenergic systems (PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385)

    What this does not mean: The warning is unchanged. Anxiety and mood effects remain community reports, and the rat data only make them plausible. PMID 9073154 still backs the dopamine and adrenergic link.

    Peptides: BPC-157

    Source: Life Sci 2004, Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain (Tohyama, Sikiric and Diksic) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  106. Evidence

    Corrected Oct 12, 2026: the HNP-1 HIV warning now cites one in vitro study in epithelial cells, after dropping an unrelated paper, per PubMed (PMID 26379091).

    Before: Demirkhanyan et al. (PMID 22647697, 2012) and a 2015 study (PMID 26379091) showed HNP-1 disrupts epithelial tight junctions, increasing HIV traversal After: A 2015 study in epithelial cell models (PMID 26379091) showed HNP-1 disrupts epithelial tight junctions, increasing HIV traversal

    What this does not mean: The warning is unchanged: anyone HIV-positive or at high risk of HIV exposure should treat HNP-1 as contraindicated.

    Peptides: Defensin (HNP-1)

    Source: Viral Immunol 2015, Human Alpha-Defensin HNP1 Increases HIV Traversal of the Epithelial Barrier (Valere et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  107. Evidence

    Corrected Oct 12, 2026: CGRP infusion set off migraine-like attacks in 79% of people with migraine (110 of 139), not 60 to 75%, per PubMed (PMID 37815254).

    Before: Delayed migraine-like headache in 60 to 75% of subjects, peaking 1 to 5 hours after infusion (cited to PMID 11952980, an unrelated paper) After: Delayed migraine-like attacks in 110 of 139 people with migraine (79%) within 12 hours of a 20-minute infusion (REFORM, PMID 37815254)

    What this does not mean: Not a new risk: CGRP infusion is the standard way studies provoke migraine. The old line cited a PMID that points to an unrelated paper.

    Peptides: CGRP (Calcitonin Gene-Related Peptide)

    Source: Cephalalgia 2023, An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study (Al-Khazali et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  108. Evidence

    Corrected Oct 12, 2026: the amylin toxicity line now cites a 2016 review of mechanisms seen in cells and animals, per PubMed (PMID 26649319).

    Before: Aggregated IAPP disrupts cell membranes, triggers ER stress, activates the NLRP3 inflammasome, and induces apoptosis (cited to PMID 14988259, an unrelated paper) After: In lab and animal studies, aggregated IAPP is linked to membrane disruption, ER stress, NLRP3 inflammasome activation, and beta-cell death (Akter et al. 2016 review, PMID 26649319)

    What this does not mean: The risk is unchanged: aggregated amylin damages beta cells. The old citation pointed to an unrelated paper; the page now calls the mechanisms linked to that damage, as the review does.

    Peptides: Amylin (IAPP)

    Source: J Diabetes Res 2016, Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology (Akter et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  109. Evidence

    Corrected Oct 12, 2026: the alpha-MSH melanoma warning now cites a 2023 review that includes preclinical data, per PubMed (PMID 37608347).

    Before: Contraindicated in active or prior melanoma (cited to PMID 20651044, an unrelated paper) After: Contraindicated in active or prior melanoma; a 2023 review reports MC1R and alpha-MSH overexpressed in metastatic melanoma (PMID 37608347)

    What this does not mean: The warning is unchanged: active or prior melanoma still rules alpha-MSH out. Only its source changed; the old citation pointed to an unrelated paper.

    Peptides: Alpha-MSH (α-Melanocyte-Stimulating Hormone)

    Source: J Transl Med 2023, Alpha-melanocyte stimulating hormone (alpha-MSH): biology, clinical relevance and implication in melanoma (Dall'Olmo et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  110. Dosing

    Corrected Oct 11, 2026: tesamorelin tiers are the EGRIFTA SV label dose, 1.4 mg once daily, not 2 mg; EGRIFTA WR is 1.28 mg, per the FDA labels.

    Before: Every tier 2 mg (2,000 mcg) daily, cited to the FDA label After: Every tier 1.4 mg (1,400 mcg) once daily, the EGRIFTA SV label dose; EGRIFTA WR, not substitutable, is 1.28 mg once daily

    Peptides: Tesamorelin

    Source: EGRIFTA SV (tesamorelin) prescribing information (openFDA label record, SPL version 9, effective Jul 29, 2026) (opens in a new tab) · Saved copy

  111. Regulatory

    Corrected Oct 10, 2026: sermorelin's US status now records that FDA withdrew both Geref approvals effective Jun 18, 2009, per Federal Register E9-11628.

    Before: No sourced US status record After: Not approved in the US. Geref NDA 019863 (Dec 28, 1990) and NDA 020443 (Sep 26, 1997) were discontinued in 2008; FDA withdrew both approvals June 18, 2009 (74 FR 23407), not for safety or effectiveness (78 FR 14095)

    What this does not mean: FDA found in 2013 that Geref was not withdrawn from sale for safety or effectiveness reasons (78 FR 14095). Compounded sermorelin is not an FDA-approved product.

    Peptides: Sermorelin

    Source: Federal Register E9-11628 (74 FR 23407, May 19, 2009): Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications, including NDA 19-863 Geref Diagnostic and NDA 20-443 Geref; effective June 18, 2009 (opens in a new tab) · Saved copy

  112. Safety

    Corrected Oct 10, 2026: sermorelin side effects drop an unsourced 70% antibody rate; on daily GHRH(1-29), antibodies seemed not to hinder growth, per PubMed.

    Before: About 70% of continuous users develop neutralizing antibodies by 18 months, credited to the Geref label After: Antibodies form in many patients, often transiently; in 16 prepubertal GH-deficient children on daily GHRH(1-29), they seemed not to interfere with growth (PMID 7735367)

    What this does not mean: Antibodies still form in many patients on the Geref label. Users who run sermorelin without breaks still report losing its effect.

    Peptides: Sermorelin

    Source: J Pediatr Endocrinol 1994, Long-term therapy with a single daily subcutaneous dose of GHRH (1-29) in prepubertal GH deficient children (PMID 7735367) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  113. Regulatory

    Corrected Oct 10, 2026: sermorelin's research stage is now discontinued, after FDA withdrew both Geref approvals effective Jun 18, 2009, per Federal Register.

    Before: Approved After: Discontinued

    What this does not mean: FDA found in 2013 that Geref was not withdrawn from sale for safety or effectiveness reasons (78 FR 14095). The trial data on this page are unchanged.

    Peptides: Sermorelin

    Source: Federal Register E9-11628 (74 FR 23407, May 19, 2009): Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications, including NDA 19-863 Geref Diagnostic and NDA 20-443 Geref; effective June 18, 2009 (opens in a new tab) · Saved copy

  114. Regulatory

    Corrected Oct 10, 2026: nesiritide's US status now records the Natrecor withdrawal (NDA 020920), effective Jun 15, 2020, per Federal Register 2020-10367.

    Before: No sourced US status record After: Not approved in the US: Natrecor NDA 020920 approval withdrawn June 15, 2020 (85 FR 28950), not for safety or effectiveness (86 FR 1516)

    What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

    Peptides: Nesiritide (Natrecor)

    Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

  115. Regulatory

    Corrected Oct 10, 2026: nesiritide's research stage is now discontinued, after the Jun 15, 2020 Natrecor withdrawal, per Federal Register 2020-10367.

    Before: Approved After: Discontinued

    What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

    Peptides: Nesiritide (Natrecor)

    Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

  116. Regulatory

    Corrected Oct 10, 2026: FDA withdrew approval of Natrecor (nesiritide, NDA 020920) effective Jun 15, 2020, per Federal Register 2020-10367.

    Before: FDA Approved After: Research (no FDA-approved product; the Natrecor approval was withdrawn as of June 15, 2020)

    What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

    Peptides: Nesiritide (Natrecor)

    Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

  117. Regulatory

    Corrected Oct 10, 2026: nesiritide's evidence label is now extensively studied, after the Jun 15, 2020 Natrecor withdrawal, per Federal Register 2020-10367.

    Before: FDA Approved After: Extensively Studied (VMAC; ASCEND-HF, n=7,141)

    What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

    Peptides: Nesiritide (Natrecor)

    Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

  118. Regulatory

    Corrected Oct 10, 2026: lixisenatide's US status now marks Adlyxin discontinued, license voluntarily revoked, and lists Soliqua 100/33, per the FDA Purple Book.

    Before: US applications: Adlyxin (BLA 208471), not marked discontinued After: US applications: Adlyxin (BLA 208471), discontinued, license voluntarily revoked; Soliqua 100/33 (BLA 208673, lixisenatide with insulin glargine), licensed

    What this does not mean: Soliqua 100/33 pairs lixisenatide with insulin glargine in one daily pen, and no lixisenatide-only product is marketed in the US. The dose and label facts on this page are unchanged.

    Peptides: Lixisenatide

    Source: FDA Purple Book, monthly data download, September 2026 (BLA 208471 Adlyxin: Disc, Voluntarily Revoked; BLA 208673 Soliqua 100/33: Rx, Licensed) (opens in a new tab) · Saved copy

  119. Regulatory

    Corrected Oct 10, 2026: gonadorelin is not on FDA's 503A bulk drug substance category lists, per the FDA 503A categories list updated May 14, 2026.

    What this does not mean: The page had said gonadorelin was in Category 1 on the 503A and 503B lists. No captured FDA list supports that, and no 503B list was checked.

    Peptides: Gonadorelin

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy

  120. Regulatory

    Corrected Oct 10, 2026: gonadorelin first gained FDA approval on Sep 30, 1982 (Factrel, NDA 018123), not in 1978, per Drugs@FDA.

    Before: No sourced US status record; the page said FDA-approved since 1978 After: US status FDA approved: Factrel NDA 018123 (Sep 30, 1982) and Lutrepulse Kit NDA 019687 (Oct 10, 1989), both discontinued

    What this does not mean: Factrel and Lutrepulse are both listed as discontinued in Drugs@FDA. Compounded gonadorelin is not an FDA-approved product.

    Peptides: Gonadorelin

    Source: Drugs@FDA record for Factrel (gonadorelin hydrochloride), NDA 018123 (openFDA): original approval Sep 30, 1982; products discontinued (opens in a new tab) · Saved copy

  121. Regulatory

    Corrected Oct 10, 2026: CCK-8 now lists two sincalide applications, Kinevac (NDA 017697, 1976) and NDA 210850 (2022), both prescription, per Drugs@FDA.

    Before: No sourced US status record After: US status FDA approved: Kinevac NDA 017697 (Jul 21, 1976) and sincalide NDA 210850 (Nov 22, 2022), both prescription

    What this does not mean: Both applications are for the same IV diagnostic drug. Neither covers appetite, weight loss or any other therapeutic use.

    Peptides: Cholecystokinin (CCK-8)

    Source: Drugs@FDA record for sincalide, NDA 210850 (openFDA): original approval Nov 22, 2022; prescription (opens in a new tab) · Saved copy

  122. Regulatory

    Corrected Oct 10, 2026: CCK-8's status now reflects FDA's Jul 21, 1976 original approval of sincalide as Kinevac (NDA 017697), not research only, per Drugs@FDA.

    Before: Research only After: FDA Approved (as sincalide: Kinevac, NDA 017697, Jul 21, 1976)

    What this does not mean: The approval covers sincalide as an IV diagnostic for gallbladder and pancreas testing. It does not cover appetite, weight loss or research vials of CCK-8.

    Peptides: Cholecystokinin (CCK-8)

    Source: Drugs@FDA record for Kinevac (sincalide), NDA 017697 (openFDA): original approval Jul 21, 1976; prescription (opens in a new tab) · Saved copy

  123. Regulatory

    Corrected Oct 10, 2026: CCK-8's research stage moves from preclinical to FDA approval, after sincalide's Jul 21, 1976 Kinevac approval, per Drugs@FDA.

    Before: Preclinical After: Approved (sincalide, Kinevac NDA 017697)

    What this does not mean: It reflects the sincalide diagnostic approval only. Appetite and weight-loss use of CCK-8 is limited to IV research studies in people.

    Peptides: Cholecystokinin (CCK-8)

    Source: Drugs@FDA record for Kinevac (sincalide), NDA 017697 (openFDA): original approval Jul 21, 1976; prescription (opens in a new tab) · Saved copy

  124. Dosing

    Corrected Oct 9, 2026: the 80 mg weekly TRT tier had no source; the label gives 50 to 400 mg every 2 to 4 weeks, per the Depo-Testosterone label.

    Before: Beginner 80 mg weekly After: No source supports this dose; removed. The beginner tier now repeats the 75 mg twice-weekly moderate dose, with a note.

    Peptides: TRT (Testosterone Replacement Therapy)

    Source: Depo-Testosterone (testosterone cypionate) prescribing information (openFDA label record, SPL version 26, effective Aug 21, 2026) (opens in a new tab) · Saved copy

  125. Dosing

    Corrected Oct 9, 2026: every teduglutide tier is the one label dose, 50 mcg/kg (0.05 mg/kg) daily, not a flat 2.5 to 5 mg, per the Gattex label.

    Before: Tiers of 2,500, 3,500 and 5,000 mcg daily (the 0.05 mg/kg dose worked out for 50, 70 and 100 kg) After: Every tier 50 mcg/kg (0.05 mg/kg) once daily, the label dose for adults and children

    Peptides: Teduglutide (Gattex/Revestive)

    Source: Gattex (teduglutide) prescribing information (openFDA label record, SPL version 20, effective Sep 5, 2025) (opens in a new tab) · Saved copy

  126. Dosing

    Corrected Oct 9, 2026: the 4 mg and 10 mg SS-31 tiers are community doses; the FORZINITY label dose is 40 mg once daily, per the FDA label.

    Peptides: SS-31 (Elamipretide)

    Source: FORZINITY (elamipretide) prescribing information (openFDA label record, SPL version 10, effective Dec 10, 2025) (opens in a new tab) · Saved copy

  127. Dosing

    Corrected Oct 9, 2026: setmelanotide starts at 2 mg daily for BBS and POMC, PCSK1 or LEPR deficiency from age 12, per the Imcivree label.

    Before: Beginner 1 mg daily (the start for children aged 6 to under 12) After: Beginner 2 mg daily, with a note that acquired hypothalamic obesity starts at 0.5 mg daily

    Peptides: Setmelanotide

    Source: Imcivree (setmelanotide) prescribing information (openFDA label record, SPL version 14, effective Apr 1, 2026) (opens in a new tab) · Saved copy

  128. Dosing

    Corrected Oct 9, 2026: romiplostim tiers are 1, 3 and 10 mcg per kg of body weight weekly, not flat mcg doses, per the Nplate label.

    Before: Tiers of 1, 3 and 10 mcg weekly (unit mcg) After: Tiers of 1, 3 and 10 mcg/kg weekly: the label start, the median responder dose (2 to 3 mcg/kg) and the 10 mcg/kg maximum

    Peptides: Romiplostim (Nplate)

    Source: Nplate (romiplostim) prescribing information (openFDA label record, SPL version 162, effective Jun 23, 2026) (opens in a new tab) · Saved copy

  129. Dosing

    Corrected Oct 9, 2026: the 1,500 mcg daily melanotan I tier had no source; the one labeled product is a 16 mg implant, per the SCENESSE label.

    Before: Aggressive 1,500 mcg daily After: No source supports this dose; removed. The aggressive tier now repeats the 1,000 mcg daily moderate dose, with a note.

    Peptides: Melanotan I

    Source: SCENESSE (afamelanotide) prescribing information (openFDA label record, SPL version 11, effective May 11, 2026) (opens in a new tab) · Saved copy

  130. Dosing

    Corrected Oct 9, 2026: the linaclotide beginner tier is 145 mcg daily, the adult CIC dose; 72 mcg is a tolerability option, per the Linzess label.

    Before: Beginner 72 mcg daily After: Beginner 145 mcg daily; 72 mcg stays a label option for CIC by presentation or tolerability

    Peptides: Linaclotide (Linzess)

    Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy

  131. Dosing

    Corrected Oct 9, 2026: the lanreotide beginner tier is the 90 mg acromegaly start every 4 weeks, not 60 mg, per the Somatuline Depot label.

    Before: Beginner 60 mg every 4 weeks After: Beginner 90 mg every 4 weeks; 60 mg is the start only with moderate or severe kidney or liver impairment

    Peptides: Lanreotide (Somatuline Depot)

    Source: Somatuline Depot (lanreotide) prescribing information (openFDA label record, SPL version 16, effective Oct 11, 2024) (opens in a new tab) · Saved copy

  132. Dosing

    Corrected Oct 9, 2026: the desmopressin top tier is 4 mcg once a day; the daily dose is 2 to 4 mcg in one or two doses, per the DDAVP label.

    Before: Aggressive 4 mcg, 1-2x daily (up to 8 mcg a day) After: Aggressive 4 mcg once daily, the top of the 2 to 4 mcg daily range

    Peptides: Desmopressin (DDAVP)

    Source: DDAVP (desmopressin acetate) injection prescribing information (openFDA label record, SPL version 15, effective Sep 28, 2022) (opens in a new tab) · Saved copy

  133. Dosing

    Corrected Oct 9, 2026: cerebrolysin tiers now read 5, 10 and 20 mL of solution, the unit trials dose it in, per ClinicalTrials.gov NCT00911807.

    Before: Tiers of 1,076, 2,152 and 4,304 mg daily (unit mg) After: Tiers of 5, 10 and 20 mL daily of the 215.2 mg/mL solution (the same amounts, in mL)

    Peptides: Cerebrolysin

    Source: ClinicalTrials.gov NCT00911807, Cerebrolysin 10 mL IV infusions in Alzheimer disease (API v2 record) (opens in a new tab) · Saved copy

  134. Dosing

    Corrected Oct 9, 2026: the calcitonin beginner tier is 100 IU daily, the injection dose for Paget disease and osteoporosis, per the Miacalcin label.

    Before: Beginner 50 IU daily; aggressive 200 IU daily with no note After: Beginner 100 IU daily by SC or IM injection; the 200 IU aggressive tier now notes it is the nasal spray dose (PROOF study), not an injection dose

    Peptides: Calcitonin (Miacalcin)

    Source: Miacalcin (calcitonin salmon) injection prescribing information (openFDA label record, SPL version 9, effective Apr 15, 2024) (opens in a new tab) · Saved copy

  135. Safety

    Corrected Oct 7, 2026: pancreatitis history, gastroparesis and pregnancy are US Adlyxin label cautions, not contraindications, per the FDA label.

    Before: History of pancreatitis or active pancreatic disease; Severe gastrointestinal disease including gastroparesis; Pregnancy and breastfeeding (no adequate human data; animal studies showed adverse fetal effects) After: History of pancreatitis, gastroparesis, and pregnancy or breastfeeding: each marked as a US Adlyxin label caution or limitation of use, not a contraindication

    Peptides: Lixisenatide

    Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) (opens in a new tab) · Saved copy

  136. Safety

    Corrected Oct 7, 2026: end-stage renal disease now reads as a label warning on the contraindication list, not a contraindication, per the US Adlyxin label.

    Before: End-stage renal disease (eGFR <15 mL/min) or dialysis: limited data and renal elimination pathway After: End-stage renal disease (eGFR <15 mL/min) or dialysis: not recommended on the US Adlyxin label (no therapeutic experience); a label warning, not a contraindication

    Peptides: Lixisenatide

    Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) (opens in a new tab) · Saved copy

  137. Safety

    Corrected Oct 7, 2026: the Linzess label contraindicates linaclotide under age 2, not under 6, and covers IBS-C from age 7, per the FDA label.

    Before: Children under 6 years of age: BOXED WARNING; not recommended for IBS-C in patients aged 6 to 17 years After: Children under 2 years of age: BOXED WARNING; IBS-C in children under 7: safety and effectiveness not established (labeled for ages 7 and older)

    What this does not mean: The label has said under 2 since August 2021. No new FDA safety action happened on this date; the page was out of date.

    Peptides: Linaclotide (Linzess)

    Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy

  138. Safety

    Corrected Oct 7, 2026: the boxed dehydration warning covers children under 2, not under 6, per the current Linzess label (SPL version 39).

    Before: The boxed warning comes first: linaclotide is contraindicated in children under 6 years of age. After: The boxed warning comes first: linaclotide is contraindicated in children under 2 years of age.

    Peptides: Linaclotide (Linzess)

    Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy

  139. Safety

    Corrected Oct 7, 2026: severe renal impairment is a Byetta label warning, not a contraindication; drug-induced thrombocytopenia is now listed, per the label.

    Before: Exenatide is renally eliminated and contraindicated when eGFR falls below 30 mL/min. After: The Byetta label does not recommend it with severe renal impairment (creatinine clearance below 30 mL/min) or end-stage renal disease. Drug-induced immune-mediated thrombocytopenia added.

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  140. Safety

    Corrected Oct 7, 2026: pregnancy and severe gastroparesis are Byetta label cautions, not contraindications, per the Byetta label.

    Before: Pregnancy or breastfeeding: not studied; potential fetal harm based on animal data; Severe gastrointestinal disease (e.g., gastroparesis) After: Pregnancy or breastfeeding: a Byetta label caution, not a contraindication; Severe gastroparesis: not recommended per the Byetta label (a warning, not a contraindication)

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  141. Safety

    Corrected Oct 7, 2026: Byetta's label contraindicates exenatide after drug-induced thrombocytopenia; kidney and pancreatitis items are warnings, per the label.

    Before: Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease; History of pancreatitis (both listed as contraindications) After: History of drug-induced immune-mediated thrombocytopenia from exenatide products (label contraindication); severe renal impairment or ESRD and pancreatitis marked as label warnings

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  142. Evidence

    Corrected Oct 7, 2026: CagriSema's investigational status now cites an active Phase 3 trial (REDEFINE 3), not a withdrawn one, per ClinicalTrials.gov.

    Before: Status source: ClinicalTrials.gov NCT07357766 only (a formulation trial withdrawn before enrolling) After: Status sources: ClinicalTrials.gov NCT05669755 (REDEFINE 3, Phase 3, active, not recruiting) and NCT07357766

    Peptides: CagriSema

    Source: ClinicalTrials.gov NCT05669755, REDEFINE 3 (CagriSema cardiovascular outcomes, Phase 3, active, not recruiting; last update posted Aug 31, 2026) (opens in a new tab) · Saved copy

  143. Evidence

    Corrected Oct 7, 2026: 4 of 16 knee pain patients in Lee and Padgett 2021 got BPC-157 with thymosin beta-4, not all 16, per PubMed (PMID 34324435).

    Before: Human combination evidence: one retrospective report of 16 patients (Lee and Padgett 2021) After: Human combination evidence: 4 patients in one retrospective report (Lee and Padgett 2021, PMID 34324435)

    What this does not mean: The other 12 patients received BPC-157 alone. Three of the four combination patients reported significant relief; the study was a retrospective chart review with no control group.

    Peptides: Wolverine Stack (BPC-157 + TB-500)

    Source: Altern Ther Health Med 2021, Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Lee and Padgett) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  144. Dosing

    Corrected Oct 6, 2026: the dosing source and FAQ now give 2026, not 2025, as the year of Foundayo's first US approval, per the FDA record.

    Peptides: Orforglipron

    Source: Drugs@FDA record for Foundayo (orforglipron), NDA 220934 (openFDA) (opens in a new tab) · Saved copy

  145. Safety

    Corrected Oct 6, 2026: the US Adlyxin label lists severe hypersensitivity as its only contraindication, not MTC or MEN 2, per the FDA label.

    Before: The precautionary contraindication for personal or family history of medullary thyroid carcinoma or MEN2 remains on the label. After: The US Adlyxin label lists severe hypersensitivity as its only contraindication.

    Peptides: Lixisenatide

    Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) (opens in a new tab) · Saved copy

  146. Safety

    Corrected Oct 6, 2026: MTC and MEN 2 history now reads as a GLP-1 class caution kept by this site, not an Adlyxin contraindication, per the FDA label.

    Before: Personal or family history of medullary thyroid carcinoma (precautionary: no boxed warning); Multiple Endocrine Neoplasia syndrome type 2 (MEN2) After: Personal or family history of medullary thyroid carcinoma (MTC) or MEN2: GLP-1 class caution kept by this site; not on the US Adlyxin label

    Peptides: Lixisenatide

    Source: Adlyxin (lixisenatide) prescribing information (openFDA label record, SPL version 13) (opens in a new tab) · Saved copy

  147. Safety

    Corrected Oct 6, 2026: the MTC and MEN 2 contraindication is on Bydureon and Bydureon BCise, not Byetta, per the Byetta and Bydureon BCise labels.

    Before: Personal or family history of medullary thyroid carcinoma (MTC): black box warning After: Personal or family history of medullary thyroid carcinoma (MTC): Bydureon and Bydureon BCise only (boxed warning); not a Byetta contraindication

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  148. Safety

    Corrected Oct 6, 2026: the boxed thyroid C-cell tumor warning is on Bydureon and Bydureon BCise, not Byetta, per the Byetta and Bydureon BCise labels.

    Before: Exenatide carries an FDA black box warning for medullary thyroid carcinoma risk. After: Bydureon and Bydureon BCise carry the boxed warning. Byetta carries no boxed warning.

    Peptides: Exenatide (Byetta / Bydureon)

    Source: Byetta (exenatide) prescribing information, SPL version 26, effective 2025-09-02 (openFDA label record) (opens in a new tab) · Saved copy

  149. Safety

    FDA made a past hypersensitivity reaction to corticotropin a contraindication for Acthar Gel on Oct 5, 2026, citing anaphylaxis and angioedema, per the label.

    Before: No corticotropin hypersensitivity line; the only hypersensitivity item named cosyntropin. After: Prior hypersensitivity to corticotropin or any inactive ingredient: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels since October 2026; reactions have included anaphylaxis and angioedema

    What this does not mean: Doses and indications did not change. It is one FDA-required change for ACTH products: Purified Cortrophin Gel gained the same contraindication the same day. No cosyntropin (Cortrosyn) label changed.

    Peptides: ACTH (Cosyntropin/Cortrosyn)

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  150. Evidence

    SYNCHRONIZE-2 found 9.8% weight loss on survodutide 6.0 mg vs 3.9% on placebo at 76 weeks in type 2 diabetes, published Oct 1, 2026, per NEJM.

    What this does not mean: A weight trial in obesity with type 2 diabetes (NCT06066528), not a MASH trial. Survodutide has no FDA approval.

    Peptides: Survodutide

    Source: N Engl J Med 2026, Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

September 2026

  1. Evidence

    ACHIEVE-4 found MACE-4 in 4.2% on orforglipron vs 5.0% on insulin glargine (HR 0.84), meeting non-inferiority, published Sep 30, 2026, per The Lancet.

    What this does not mean: Non-inferiority, not a shown heart benefit (95% CI 0.59 to 1.20). It enrolled adults with type 2 diabetes, an indication Foundayo does not have in the US.

    Peptides: Orforglipron

    Source: Lancet 2026, Cardiovascular safety of orforglipron versus insulin glargine (ACHIEVE-4) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  2. Evidence

    TRIUMPH-2 reported 18.8% weight loss on retatrutide 12 mg vs 5.1% on placebo at 80 weeks in type 2 diabetes, published Sep 29, 2026, per The Lancet.

    What this does not mean: Treatment-regimen figures in 1,152 adults with obesity and type 2 diabetes. Lilly's July 2026 topline of 20.8% used the efficacy estimand.

    Peptides: Retatrutide

    Source: Lancet 2026, Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  3. Safety

    TRIUMPH-2 found more hypotension (up to 6% vs under 1%) and dysesthesia (up to 7% vs 1%) on retatrutide, published Sep 29, 2026, per The Lancet.

    Before: No hypotension text; dysesthesia cited from Lilly toplines only, with TRIUMPH-1 labeled not yet peer-reviewed. After: TRIUMPH-2 (Lancet 2026): hypotension 1 to 6% vs under 1% on placebo; dysesthesia 4 to 7% vs 1%; diarrhea and nausea led.

    What this does not mean: Rates rose with dose (hypotension 1%, 5%, 6% on 4, 9, 12 mg). The trial was not designed to test blood pressure safety.

    Peptides: Retatrutide

    Source: Lancet 2026, Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  4. Evidence

    TRIUMPH-1 reported 25.0% weight loss on retatrutide 12 mg vs 3.9% on placebo at 80 weeks, published Sep 29, 2026, per NEJM.

    What this does not mean: These are treatment-regimen figures that count everyone randomized. Lilly's 28.3% topline used the efficacy estimand. Retatrutide has no FDA approval.

    Peptides: Retatrutide

    Source: N Engl J Med 2026, Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  5. Safety

    In a US registry of 140 children on teduglutide, the share with low weight-for-age rose from 2.3% to 12.7% by year 3, published Sep 17, 2026, per Pediatr Res.

    What this does not mean: A registry with no comparison group, so the drug is not shown to cause it. Parenteral calories fell 49.5% by year 3; the authors advise watching nutrition.

    Peptides: Teduglutide (Gattex/Revestive)

    Source: Pediatr Res 2026, Safety and long-term effectiveness of teduglutide in children with intestinal failure (NCT04832087) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

August 2026

  1. Evidence

    Bivalirudin's edge over heparin in STEMI was not larger at high bleeding risk, per a prespecified BRIGHT-4 analysis in JACC, Aug 28, 2026.

    What this does not mean: It does not show bivalirudin fails at high bleeding risk. Absolute reductions were similar (1.1 vs 1.5 points), and the authors concluded the benefit applied to both groups.

    Peptides: Bivalirudin (Angiomax)

    Source: Journal of the American College of Cardiology 2026, BRIGHT-4 by baseline bleeding risk (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  2. Safety

    Mounjaro's existing diabetic retinopathy warning (5.7) was revised on Aug 27, 2026, per the FDA label; no new retinopathy warning was added.

    Peptides: Tirzepatide

    Source: Mounjaro (tirzepatide) prescribing information, SPL version 40, effective 2026-08-27 (openFDA label record) (opens in a new tab) · Saved copy

  3. Regulatory

    FDA added a major adverse cardiovascular event risk indication in type 2 diabetes to Mounjaro (S-044, S-045) on Aug 27, 2026, per the updated FDA label.

    What this does not mean: SURPASS-CVOT showed noninferiority to dulaglutide, not superiority. Zepbound did not gain this indication.

    Peptides: Tirzepatide

    Source: Mounjaro (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 27, 2026) (opens in a new tab) · Saved copy

  4. Safety

    FDA ended the Gattex (teduglutide) REMS safety program on Aug 26, 2026, finding it no longer necessary, per FDA's letter on NDA 203441 supplement 28.

    What this does not mean: The risks it covered still apply: possible tumor and polyp growth, bowel blockage, and gallbladder, bile duct and pancreas problems. FDA found specialists wrote about 80% of 2020-2024 prescriptions.

    Peptides: Teduglutide (Gattex/Revestive)

    Source: FDA supplement approval letter, Gattex (teduglutide) NDA 203441/S-28, Aug 26, 2026: "a REMS is no longer required for Gattex" (opens in a new tab) · Saved copy

  5. Safety

    Zepbound supplement S-041 revised the existing diabetic retinopathy warning (5.8) on Aug 26, 2026, per the updated label; no cardiovascular indication.

    Peptides: Tirzepatide

    Source: Zepbound (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 28, 2026) (opens in a new tab) · Saved copy

  6. Evidence

    A US Phase 2 trial found 18.1% weight loss on mazdutide 16 mg vs 0.9% on placebo at 32 weeks, published Aug 21, 2026, per Lancet Diabetes Endocrinol.

    What this does not mean: An efficacy-estimand result in 179 adults without diabetes. 16 mg is above the 9 mg top dose on this page and is not a dosing recommendation.

    Peptides: Mazdutide

    Source: Lancet Diabetes Endocrinol 2026, Mazdutide in adults with obesity or overweight: US Phase 2 trial (NCT06124807) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  7. Safety

    A meta-analysis of 8 observational cohorts (5.9 million people) linked semaglutide to NAION (RE 1.93), published Aug 18, 2026, per J Clin Pharmacol.

    Before: No NAION or optic neuropathy text. After: NAION paragraph: observational meta-analysis (8 cohorts, RE 1.93, 95% CI 1.22 to 3.08), very rare, same-day care for sudden vision loss.

    What this does not mean: An observational association with high heterogeneity, not proof of cause. The current US Wegovy, Ozempic and Rybelsus labels do not list NAION.

    Peptides: Semaglutide

    Source: J Clin Pharmacol 2026, Semaglutide and nonarteritic anterior ischemic optic neuropathy: systematic review and meta-analysis (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  8. Evidence

    ApoB, a heart-risk marker, fell 24.2% on retatrutide 12 mg vs 6.8% on placebo in phase 2, published Aug 17, 2026, per Diabetes Obes Metab.

    What this does not mean: Post hoc and Lilly-funded. The 24.2% came at 48 weeks in people without type 2 diabetes. In type 2 diabetes at 36 weeks, apoB fell 21.4% (8 mg) and 17.7% (12 mg) vs a 0.2% rise on placebo. Heart outcomes are unknown.

    Peptides: Retatrutide

    Source: Diabetes Obes Metab 2026, Retatrutide-associated improvements in cardiovascular risk biomarkers in adults with obesity with or without type 2 diabetes (post hoc, two phase 2 trials) (opens in a new tab) · Archived snapshot (opens in a new tab)

  9. Safety

    In ACHIEVE-J, 14% stopped orforglipron 36 mg for side effects vs 5% on 3 mg over 52 weeks, published Aug 17, 2026, per Lancet Diabetes Endocrinol.

    What this does not mean: An open-label safety trial in 401 Japanese adults with type 2 diabetes, with no placebo arm. Most side effects were mild, and none had severe hypoglycemia.

    Peptides: Orforglipron

    Source: Lancet Diabetes Endocrinol 2026, Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J) (opens in a new tab) · Archived snapshot (opens in a new tab)

  10. Safety

    A meta-analysis of 32 tirzepatide and semaglutide trials found more hypotension-related events on tirzepatide (RR 2.45), published Aug 15, 2026, per Endocrine.

    Before: No hypotension text. After: Hypotension paragraph: Zepbound label 1.6% vs 0.1% on placebo; meta-analysis RR 2.45 (95% CI 1.35 to 4.45), higher at higher doses.

    What this does not mean: Hypotension stays uncommon: the Zepbound label reports 1.6% vs 0.1% on placebo, higher with blood pressure drugs or GI fluid loss.

    Peptides: Tirzepatide

    Source: Endocrine 2026, Effect of tirzepatide and semaglutide on blood pressure: systematic review and meta-analysis (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  11. Evidence

    In healthy men, daily 8-hour kisspeptin-10 infusions kept LH up for 12 days; continuous infusion faded by day 5, per Eur J Endocrinol, Aug 4, 2026.

    Before: Desensitization evidence came only from daily kisspeptin-54 in women with hypothalamic amenorrhea (PMID 19820030). After: Adds kisspeptin-10 data in healthy men: continuous infusion lost the LH and FSH rise by day 5; 8 hours on, 16 off kept LH raised for 12 days (PMID 42549827).

    What this does not mean: The study used subcutaneous pump infusions in 15 men, not daily injections, so it does not test community injection doses. The dose tiers on this page are unchanged.

    Peptides: Kisspeptin-10

    Source: European Journal of Endocrinology 2026, chronic subcutaneous kisspeptin-10 in healthy men (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

July 2026

  1. Regulatory

    PCAC backed Semax for the 503A bulks list 8-5-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: Semax

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  2. Regulatory

    PCAC recommended epitalon for the 503A bulks list on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: Epithalon

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  3. Regulatory

    PCAC did not back emideltide (DSIP) for the 503A list 6-7-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote is advice to FDA, not a decision. Emideltide stays off the 503A bulks list unless FDA adds it by notice-and-comment rule.

    Peptides: DSIP

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  4. Regulatory

    PCAC backed TB-500 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: TB-500

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  5. Regulatory

    PCAC backed MOTS-c for the 503A bulks list 7-5-2 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: MOTS-c

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  6. Regulatory

    PCAC backed KPV for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: KPV

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  7. Regulatory

    PCAC backed BPC-157 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: BPC-157

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  8. Evidence

    In rats, BPC-157 plus TB-500 gave no added Achilles tendon benefit over either peptide alone, per Jt Dis Relat Surg, Jul 23, 2026.

    What this does not mean: One small rat study: 8 rats per group, 4 weeks of intraperitoneal injections. It did not test people or the pre-mixed vial, and it does not show the stack slows healing.

    Peptides: Wolverine Stack (BPC-157 + TB-500), TB-500, BPC-157

    Source: Joint Diseases and Related Surgery 2026, BPC-157 and TB-500 on Achilles tendon healing in rats (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  9. Evidence

    In mice, thymulin improved tumor control and response to anti-PD-L1 therapy in an age-dependent way, per Nature Communications, Jul 21, 2026.

    Before: Checkpoint inhibitors: combined T-cell activation effects are unstudied and could be unpredictable After: Checkpoint inhibitors: no human combination data; in aged mice thymulin improved anti-PD-L1 response (PMID 42481458); effects in people could be unpredictable

    What this does not mean: No published study has given thymulin with a checkpoint inhibitor to people. The page still advises against combining them, and active cancer stays a contraindication.

    Peptides: Thymulin (FTS)

    Source: Nature Communications 2026, thymulin restrains age-associated myeloid inflammation (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  10. Safety

    Younger age and pasireotide were tied to higher gallstone risk across three somatostatin analogs, per Clin Transl Gastroenterol, Jul 20, 2026.

    Before: Gallstones described per drug as a somatostatin analog effect, with no comparison across octreotide, lanreotide and pasireotide. After: Adds a 2026 analysis: gallstones were the most common biliary event for all three; its authors found higher risk in younger patients and with pasireotide.

    What this does not mean: Adverse event reports cannot give rates, and the trials were in polycystic kidney and liver disease. It does not mean octreotide or lanreotide carry a low gallstone risk.

    Peptides: Octreotide (Sandostatin), Lanreotide (Somatuline Depot), Pasireotide (Signifor)

    Source: Clinical and Translational Gastroenterology 2026, octreotide, lanreotide and pasireotide in polycystic kidney and liver disease (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  11. Evidence

    Two Novo Nordisk CagriSema formulation trials (NCT07357740, NCT07357766) were withdrawn before enrolling anyone, posted Jul 9, 2026, per ClinicalTrials.gov.

    What this does not mean: Both records say "withdrawn due to strategic reasons" with zero enrolled. It is not a safety or efficacy signal.

    Peptides: CagriSema

    Source: ClinicalTrials.gov NCT07357766 (and NCT07357740), CagriSema versions compared (opens in a new tab) · Saved copy

  12. RegulatoryEffective

    Enfuvirtide's US status now records the Fuzeon withdrawal (NDA 021481), effective Aug 5, 2026, per Federal Register 2026-13616.

    Before: No sourced US status record After: Not approved in the US: Fuzeon NDA 021481 approval withdrawn August 5, 2026 (91 FR 41045)

    What this does not mean: The holder told FDA that Fuzeon was no longer marketed and asked for the withdrawal. The TORO trial data on this page are unchanged.

    Peptides: Enfuvirtide (Fuzeon)

    Source: Federal Register 2026-13616 (91 FR 41045, Jul 6, 2026): Withdrawal of Approval of 34 New Drug Applications, including NDA 021481 Fuzeon; approval withdrawn as of August 5, 2026 (opens in a new tab) · Saved copy

  13. RegulatoryEffective

    Enfuvirtide's research stage is now discontinued, after the Aug 5, 2026 Fuzeon withdrawal, per Federal Register 2026-13616.

    Before: Approved After: Discontinued

    What this does not mean: The holder told FDA that Fuzeon was no longer marketed and asked for the withdrawal. The TORO trial data on this page are unchanged.

    Peptides: Enfuvirtide (Fuzeon)

    Source: Federal Register 2026-13616 (91 FR 41045, Jul 6, 2026): Withdrawal of Approval of 34 New Drug Applications, including NDA 021481 Fuzeon; approval withdrawn as of August 5, 2026 (opens in a new tab) · Saved copy

  14. RegulatoryEffective

    FDA withdrew approval of Fuzeon (enfuvirtide, NDA 021481) effective Aug 5, 2026, at the holder's request, announced Jul 6, 2026, per Federal Register.

    Before: FDA Approved After: Research (no FDA-approved product; the Fuzeon approval was withdrawn as of August 5, 2026)

    What this does not mean: The holder told FDA that Fuzeon was no longer marketed and asked for the withdrawal. The TORO trial data on this page are unchanged.

    Peptides: Enfuvirtide (Fuzeon)

    Source: Federal Register 2026-13616 (91 FR 41045, Jul 6, 2026): Withdrawal of Approval of 34 New Drug Applications, including NDA 021481 Fuzeon; approval withdrawn as of August 5, 2026 (opens in a new tab) · Saved copy

  15. RegulatoryEffective

    Enfuvirtide's evidence label is now extensively studied, after the Aug 5, 2026 Fuzeon withdrawal, per Federal Register 2026-13616.

    Before: FDA Approved After: Extensively Studied (TORO-1 and TORO-2, 995 patients)

    What this does not mean: The holder told FDA that Fuzeon was no longer marketed and asked for the withdrawal. The TORO trial data on this page are unchanged.

    Peptides: Enfuvirtide (Fuzeon)

    Source: Federal Register 2026-13616 (91 FR 41045, Jul 6, 2026): Withdrawal of Approval of 34 New Drug Applications, including NDA 021481 Fuzeon; approval withdrawn as of August 5, 2026 (opens in a new tab) · Saved copy

June 2026

  1. Regulatory

    FDA extended comments on its 503B proposal for semaglutide, tirzepatide and liraglutide to Jul 30, 2026, per Federal Register 2026-12937.

    What this does not mean: An extension of the comment period only. FDA has not made a final decision on the proposal.

    Peptides: Semaglutide, Tirzepatide, Liraglutide

    Source: Federal Register 2026-12937 (91 FR 38719, Jun 26, 2026) (opens in a new tab) · Saved copy

  2. Evidence

    Lilly posted a pre-approval expanded access program for retatrutide on ClinicalTrials.gov on Jun 5, 2026, per NCT07629401.

    What this does not mean: Expanded access is not an FDA approval. It is limited to adults with severe obesity and serious complications who cannot join a trial.

    Peptides: Retatrutide

    Source: ClinicalTrials.gov NCT07629401, Pre-approval Expanded Access of Retatrutide (LY3437943) (opens in a new tab) · Saved copy

May 2026

  1. Regulatory

    FDA put non-injectable GHK-Cu back in 503A category 1 after a nominator kept that route, per the FDA 503A categories list updated May 14, 2026.

    What this does not mean: Category 1 means under evaluation. It is not the 503A bulks list, and injectable GHK-Cu stays out of every category.

    Peptides: GHK-Cu

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy

  2. Regulatory

    FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list on May 1, 2026, per Federal Register 2026-08552.

    What this does not mean: A proposal, not a final decision. It does not touch the FDA-approved brand products; it concerns bulk substances for outsourcing facilities.

    Peptides: Semaglutide, Tirzepatide, Liraglutide

    Source: Federal Register 2026-08552 (91 FR 23431, May 1, 2026) (opens in a new tab) · Saved copy

April 2026

  1. Regulatory

    FDA took non-injectable GHK-Cu off 503A category 1 on Apr 22, 2026 after its nominations were withdrawn, per the FDA 503A categories list.

    What this does not mean: It concerns 503A compounding nominations only. It is not a new FDA safety finding about GHK-Cu.

    Peptides: GHK-Cu

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026) (opens in a new tab) · Saved copy

  2. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Peptides: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  3. Regulatory

    FDA granted original approval to Foundayo (orforglipron, NDA 220934) on Apr 1, 2026, per Drugs@FDA.

    What this does not mean: The approval covers the Foundayo product and its labeled uses only.

    Peptides: Orforglipron

    Source: Drugs@FDA record for Foundayo, NDA 220934 (openFDA) (opens in a new tab) · Saved copy

February 2026

  1. Safety

    Zepbound labeling supplement S-042 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.

    Peptides: Tirzepatide

    Source: Zepbound (tirzepatide) prescribing information (openFDA label record, SPL version 40; Recent Major Changes lists the warning as removed 02/2026) (opens in a new tab) · Saved copy

  2. Safety

    Wegovy labeling supplement S-033 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per Drugs@FDA.

    Peptides: Semaglutide

    Source: Drugs@FDA record for Wegovy, NDA 215256 (openFDA) (opens in a new tab) · Saved copy

  3. Safety

    Saxenda labeling supplement S-025 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.

    Peptides: Liraglutide

    Source: Saxenda (liraglutide) prescribing information (openFDA label record, SPL version 22, effective Feb 25, 2026) (opens in a new tab) · Saved copy

January 2026

  1. Safety

    FDA asked makers to take the suicidal behavior and ideation warning off Saxenda, Wegovy and Zepbound labels on Jan 13, 2026, per an FDA safety communication.

    What this does not mean: FDA found no increased risk of suicidal ideation or behavior in its review. The diabetes-only GLP-1 labels never carried this warning.

    Peptides: Liraglutide, Semaglutide, Tirzepatide

    Source: FDA Drug Safety Communication, Jan 13, 2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications (opens in a new tab) · Saved copy

September 2025

  1. Regulatory

    FDA warning letters dated Sep 9, 2025 say drugs compounded with retatrutide are not eligible for the 503A or 503B exemptions, per FDA.

    What this does not mean: It is not an FDA safety finding about retatrutide itself. It concerns compounded products; Lilly's trial drug and expanded access program are separate.

    Peptides: Retatrutide

    Source: FDA warning letter MARCS-CMS 715506, Sep 9, 2025 (compounded retatrutide) (opens in a new tab) · Saved copy

April 2013

  1. Evidence

    The Lancet posted an expression of concern on Apr 6, 2013 about the cited tesofensine trial (PMID 18950853), per PubMed (PMID 23561987).

    Peptides: Tesofensine

    Source: Expression of concern, Lancet 2013 Apr 6, PMID 23561987 (on PMID 18950853) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

What Counts as a Change

  • Regulatory. FDA approvals and label changes, moves on the 503A and 503B compounding lists, and advisory committee outcomes.
  • Safety. New label warnings, edits to side effects or contraindications, and flags on a study a page cites, such as a retraction.
  • Dosing. Any change to the dosing tiers or dose units shown on a peptide page.
  • Evidence. New trial results, trials withdrawn or stopped early, and changes to a peptide's evidence grade.
  • Correction. A fix to an earlier entry. The original stays in place, marked with the date it was corrected.

Rewording a paragraph is not a change. A new number, warning or status is.

How Entries Are Sourced

Each entry cites one primary source: an FDA page, the Federal Register, ClinicalTrials.gov, or the study itself on PubMed. Regulator documents are saved as a copy on this site, so the source still reads the same if the original page moves. Journal articles link to an archived snapshot.

Advisory committee votes can come out months before FDA posts its minutes. Until then, the entry says the result was reported from the meeting, and it gives no count when reports disagree.

Status changes carry one line on what they do not mean. A committee vote, for example, is not an FDA rule.

Entries are not deleted. A correction gets its own dated entry.

Dates on Peptide Pages

Each peptide page shows the date its content was last reviewed and how many changes are logged for it. That line links to the page's own change list.

A page's last-updated date moves only when a change is logged here or its dosing, safety or status data changes. A routine review updates the reviewed date and nothing else.

Browse all 150 peptides or read the editorial policy.